2023

Non-linear dilution adjustment of exemplary urine arsenic

PART II - SEX-AND AGE-SPECIFIC DIFFERENCES

THOMAS CLEMENS CARMINE MD

Etzelstrasse 21 • 8808 Pfäffikon SZ • Switzerland • Tel +41 55 415 50 30 • research@dr-carmine.ch

Non-linear dilution adjustment of exemplary urine arsenic
Part II: Sex- and Age-specific Differences

Contents

ABSTRACT **2**

1. INTRODUCTION **3**

1.1. Variable power functional creatinine correction (V-PFCRC) 3
1.2. Sex differences in osmoregulation, urinary dilution, and uCR 3
1.3. Sex differences in renal arsenic excretion 5
1.3. Influence of age on renal function and fluid balance 5
1.4. Influence of age on renal arsenic excretion 7
1.5. Influence of kidney function on arsenic excretion 8

2. STUDY POPULATION **9**

3. METHODS/STATISTICS **9**

4. RESULTS **10**

4.1. Effects of sex on uCR and TWuAs 10
4.2. Effects of age on uCR and TWuAs 11
4.3. Effects of age and sex on V-PFCRC equations 11
4.4. Validation of V-PFCRC 12

5. DISCUSSION **13**

5.1. Sex differences 13
5.2. Influence of age 14
5.3 Pivotal role of osmoregulation in age-/sex-variations of V-PFCRC functions 15
5.4. Validation, advantages, and limitations of V-PFCRC 17

6. CONCLUSIONS / KEY MESSAGES **18**

7. ABBREVIATIONS **19**

8. ACKNOWLEDGEMENTS **20**

9. AUTHOR CONTRIBUTION **20**

10. CONFLICT OF INTEREST **20**

11. ETHICS **20**

12. FUNDING **20**

13. REFERENCES **21**

14. SUPPLEMENTARY MATERIAL / APPENDICES **35**

Appendix 1: Sex differences and influence of sex hormones on renal membrane transporters. 35
Appendix 2: Physiological sex differences and influence of sex hormones on basic urinary parameters. 35
Appendix 3: Physiological sex differences and influence of sex hormones on basic renal parameters. 35
Appendix 4: Physiological sex differences and influence of sex hormones on fluid distribution parameters. 36
Appendix 5: Influence of age on medians and ICRs of uCR and TWuAs. 36
Appendix 6: Quantitative sex differences of TWuAs within uAs_{UC}, uAs_C, and uAs_N. 37
Appendix 7: Increase in As_N with age between the end of puberty and the seventh decade of life. 37
Appendix 8: Pearson correlation of age with uCR and TWuAs. 38
Appendix 9: Sex- and age-differentiated efficacy of standardization in trimmed data sets. 38
Appendix 10: Effect of age on sex-differentiated urine osmolality (Perucca J et al., 2006). 39

Non-linear dilution adjustment of exemplary urine arsenic
Part II: Sex- and Age-specific Differences

Thomas Clemens Carmine MD

Abstract

Background
In the first part of this study, a variable power-functional creatinine correction (V-PFCRC), normalizing results to 1 g/L creatinine (uCR), was established for total weight spot-urinary arsenic (TWuAs) as an adequate method of urinary dilution. In this second part, the impact of age and sex on TWuAs, V-PFCRC functions, and fluid regulation was investigated in the identical dataset of the first part based on a comprehensive literature review.

Methods
All samples with age indication, $uAs_{UC} \leq 500$ µg/L, and uCR < 4.5 g/L (n=5585, females n= 2967, males n = 2618) were classified into seven age groups, for which sex-aggregate and disaggregate means ± SEs, medians, and ICRs were calculated for uCR and TWuAs in uncorrected (uAs_{UC}), classical CR corrected (CCRC, uAs_C), and V-PFCRC (uAs_N) results mode. In addition, Pearson correlation analyses were performed for uCR and TWuAs with age. In addition, sex-aggregated and disaggregated V-PFCRC functions were compared between three numerically similar age groups. Finally, the efficacy of creatinine correction error (CRCE) compensation was assessed by simple power-functional regression analysis (PFRA) in both sexes and seven age bands.

Findings
The clear male dominance of uAs_{UC} ($p < 0.001$) in aggregate age data and all five adult subgroups separately was inverted by CCRC (uAs_C, $p = 0.011$) and neutralized by V-PFCRC (uAs_N, $p = 0.19$). Children and adolescents did not exhibit significant sex variations in TWuAs or uCR. A continuous rise in TWuAs with age from adolescence to the beginning of the seventh decade of life was observed in uAs_{UC}, uAs_C, and uAs_N (0.28 µg/1 g uCR/year). Conversely, TWuAs decreased from childhood to adolescence and in the highest age group. Pearson analysis for all patients between 14 - 72 years and $uAs_{UC} \leq 500$ µg/L revealed significant weak positive correlations ($p < 0.001$) between TWuAs and age. The log curves between the coefficient *a* (= uAs_N) and exponent *b* ran higher in younger men and both sexes among seniors, in broad analogy with reportedly higher baseline renal vasopressor activities of angiotensin II (ATII) and arginine vasopressin (AVP, V1) in these subgroups. The efficacy of V-PFCRC was established based on minimized residual biases of uCR on uAs_N in both sexes and all seven age bands (R_2 0.0029 - 7.0E-09).

Interpretation
Sex differences in uAs_{UC} and uAs_C are primarily attributable to distinct urinary dilution and thus are compensated by V-PFCRC. In contrast, age-dependent increases in TWuAs, evident in all results modes, are genuine and should be further accounted for in exposure studies and normal range determinations. While sex and age affect V-PFCRC formulas analog to baseline vasopressor activities of ATII/AVP, they only negligibly affect the correction validity. Adequate perception of power-functional relations between uCR and uAs_{UC} alone, even neglecting these minor sex- and age-specific differences in V-PFCRC correction formulas, results in substantial improvement of dilution adjustment.

Keywords
Non-linear dilution adjustment, Spot urine, Biomarkers, Arsenic, Sex-age-differences, Exposure studies

Non-linear dilution adjustment by the example of urinary arsenic
Part II: Sex- and Age-specific Differences

Thomas C. Carmine MD

1. Introduction

1.1. Variable power functional creatinine correction (V-PFCRC)

In the first part of this study, the algebraic method of variable power-functional creatinine correction (V-PFCRC) was established as an adequate method of urinary dilution adjustment.[1] Efficient standardization of the analyte to 1 g/l urinary creatinine (uCR) by V-PFCRC was achieved by accounting for non-linear, variable power-functional relations between uCR and total weight urinary arsenic (TWuAs). The method represents a progression of previous, more simplistic dilution adjustments assuming inadequate linear (CCRC) or simple power-functional relations (S-PFCRC) between the masses of analyte and urinary creatinine (uCR) over a broad range of urinary flow rates (UFR). In contrast to CCRC and S-PFCRC, the corrective V-PFCRC equation yielded stable uAs_N results over wide ranges of (uCR) and TWuAs as an exemplary analyte by accounting for biases by both uCR and analyte range:

$$uA_N = uA_{UC} \times uCR^{-[LN(uA_{UC}) + d/c]/[Ln(uCR) + 1/c]}$$

uA_N = standardized analyte
uA_{UC} = uncorrected analyte
c and d: numerically derived analyte-specific coefficients

Apart from the analytical determination of the power-functional relationship between the TWuAs and uCR in the aggregate study population, the large sample size of n=5599 also allowed analyses of the influence of age and sex on the creatinine correction error (CRCE), which will be the subject of this second part of the study.

1.2. Sex differences in osmoregulation, urinary dilution, and uCR

The known sex differences in urinary dilution and their hormonal-physiological backgrounds are summarized in Tables 1 and 2. Women tend to produce somewhat higher weight-adjusted 24 h urine volumes. They usually display higher water turnover and natriuresis and lower urinary concentration, osmolality (uOsm), total excreted osmotic load, and uCR than men. Sex hormones influence uCR in various ways. Androgens promote higher lean muscle mass and accelerate energy metabolism.[2] The higher metabolic turnover generates larger amounts of nitrogenous waste products such as urea, uric acid, and creatinine (CR) from the breakdown of creatine. The kidneys compensate for the excess production of CR in males mainly by increased glomerular filtration, which is proportional to its plasma concentration and renal plasma flow for free-filterable CR. Additionally, male sex hormones promote the tubular secretion of CR by upregulating its major tubular CR transporters for basolateral uptake (OCT2) and apical excretion (MATE1).[1] Conversely, both transporters, OCT2 and MATE1, are inhibited by estrogen (Apps. 1, 2). Male hormones enhance the release and renal actions of the renin-angiotensin-aldosterone-system (RAAS, Tbl.1a) and Arginine-Vasopressin (AVP, Tbl.1b) at various regulatory levels: Androgens sensitize AVP-immunoreactive neurons in the limbic system implicating increased plasma AVP/Osm ratios. They also potentiate the renal tubular actions of AVP by proliferating renal AVP-binding sites and inhibiting the release of the natural AVP antagonist NT-proBNP. In such a manner, male sex hormones promote AVP-dependent reabsorption of water and sodium, conferring higher

urinary concentration and uCR. In contrast, female hormones generally have an inhibitory effect on the antidiuretic and mostly anti-natriuretic effects of AVP, be it directly on the hypothalamic-pituitary axis (HPA) and kidneys or mediated by stimulation of female-dominant renal prostaglandins (PGs) and NT-proBNP (Tbl.1b). Vasodilator PGs raise the tubular ionic permeability, reduce the cortico-medullary solvent gradient, and attenuate the effects of angiotensin II (ATII) and AVP, thus increasing medullary and papillary plasma flow. All these mechanisms favor the higher water turnover, natriuresis, more dilute urine, and lower extracellular volumes seen in women.

Table 1A: Sex-differential hormonal regulation of osmo- and fluid balance by the RAAS.

A. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (RAAS)	Female	Estrogen (E) / Progesterone (P) Effects	Male	Androgen Effects	References
Plasma Renin	↓	E ↓ P indirect (↑) via natriuresis	↑	↑	40, 41
Plasma Angiotensinogen	↑	↑	↑	?	40, 41
ACE Activity	ACE↓, ACE2↑	E ACE ↓, ACE2 ↑ P (↑) Natriuresis	ACE ↑, ACE2 ↓	ACE ↑, ACE2 ↓	40, 41
Plasma Angiotensin II (ATII)	Physiological ↓	E ↓ (angiotensin (1-7) ↑) P ↑ indirect via Natriuresis [a]	↑	↑ Angiotensin (1-7) ↓	40
	oral E/Anticonception: ↑	↑			
Plasma Aldosterone (ALD)	high Na+ diet: ↓ low Na+ diet: —	endogenous E ↓ oral E ↑	high Na+ diet: ↑ low Na+ diet: —		112, 41
Adrenal ALD response to exogenous ATII	↑		↓		112
Angiotensin-Receptor AT1R/AT2R	E ↓ P ↑ (but no effect on BP)	E: Density AT1R ↓, AT2R ↑ P: AT1R-Density↑	↑	AT2R-density ↓	40, 41, 105, 113, 115
Overall RAS activity	↓		↑	Renin ↑, ACE ↑	40, 41, 125
Effects of aging on RAAS	Plasma Renin ↓, ALD ↓, ATII ↓ → Na^+- conservation ↓ and urinary concentration ability ↓ → Hyponatremia, Hyperkaliemia, Fluid imbalances Disruption of renal RAAS activity and responsiveness: hypersensitivity to Ang II → GFR↓, RPF↓, GCHP↑, m-KL↓ → Glomerular/Tubular damage/CKD SIRT1 in aging ↓ → AT1R expression in smooth muscle cells↑ → Vasopressor Effects of ATII ↑/ Vascular remodelling/ Mitochondrial damage				86
Role of ATII / RAAS in CKD	**Systemic:** Thirst/fluid intake↑, RBF↓, sympathetic activity↑, systemic ABP↑ **Glomerular:** 1) Initial stages of CKD: Vasoconstriction of afferent < efferent glomerular arteriole → GCHP↑ → Hyperfiltration 2) Mesangial proliferation, podocyte impairment via AT1R activation by local Ang II → Proteinuria ↑, Glomerulosclerosis ↑ 3) Advanced stages of CKD: Chronic conditions like arterial hypertension, diabetes, CKD, CHD, toxic built up → Oxidative stress ↑ → ATII effect on afferent arteriole constriction ↑ → GFR ↓ **Tubular:** Na-/H_2O-retention↑ (mediated by ALD and modulated by hemodynamic changes in peritubular capillaries), uOsm↓, induces Tubular cell hypertrophy, Oxidative stress, and Apoptosis. **Hormonal / Regulatory:** Klotho ↓, AVP release from HPA↑, ALD↑ **Pro-sclerotic/-oxidative/-inflammatory:** proinflammatory and profibrotic cytokine-like actions. Synergistic profibrotic effects of Renin and ALD → (TGF- β↑); Ang II + TGF-β → Oxidative stress → Extracellular matrix synthesis ↑/ Matrix degradation ↓				72, 92, 126, 127, 128, 129

[a] Ang II can conversely produce dose- and time-dependent stimulatory effects on progesterone secretion in human granulosa cells,[40] as ACEs and the RAAS in general play a pivotal role in fertility.[146]

Table 1B: Sex-differential hormonal regulation of osmo- and fluid balance by vasopressin (AVP).

B. VASOPRESSIN (AVP, ADH)/ NT-proBNP	Female	Estrogen/Progesterone Effects	Male	Androgen Effects	References
Osmotic threshhold for AVP Release and thirst Homoeostatic setpoint	Osmotic threshhold ↓ → AVP release starts at lower pOsm	E: direct effect on pituary/ hypothalamus [a]	Osmotic threshold ↑ → AVP release starts at higher pOsm	?	97, 117, 130, 131, 132
Plasma AVP Slope (pAVP/pOsm ratio)	↓ lower AVP release on hyperosmolar stimulus		↑ higher AVP release on hyperosmolar stimulus	**direct:** steroid-responsive, AVP-immunoreactive neurons in limbic system↑ **indirect:** BNP↓ → AVP-Inhibition ↓	97, 131, 133, 134
Basal Plasma AVP	↓		↑		6, 85
Urine AVP	↓		↑		6
Renal AVP Responsiveness, AVP-induced antidiuresis	↓	**E direct ↓:** urine flow↑, uOsm↓ **E indirect ↓:** PG↑,AT2R↑,AQP↓ **P indirekt:** competitive inhibition of ALD	↑ AVP-stimulation of cAMP ↑ Density of V2-Receptors (V2R) in CKD↑	T increases renal AVP-Binding-sites (young<middle>aged)	6, 85, 132, 135, 136, 137
AVP V2 Receptor (V2R) density collecting duct	↓		↑		6
Renal AVP Clearance	↓		↑		6
Effect of aging on plasma AVP	↑ (↓) (inconclusive)		↑(↓) (inconclusive)		138, 139
Effect of aging on renal AVP sensitivity	↓		↓		137, 139
Deleterious effects of AVP in CKD	AVP ↑ aggravates CKD by: 1. Vasoconstriction of afferent arterioles (V1a) + Na^+-/H_2O-Retention (V2) → ABP↑→ Glomerular damage & sclerosis↑ 2. AVP → V2-R-stimulation ↑ (direct) + Na^+-load to macula densa ↓ (indirect) → Renin↑→ RAAS ↑ → Proteinuria + ABP↑ 3. RAAS ↑ → Constriction of efferent arteriole → initial hyperfiltration (GFR ↑) → glomerular damage → Proteinuria + GFR↓ 4. AVP↑ (direct and indirect via ALD↑) → Klotho↓ → Vitamin 1,25D production↑ → serum PO4 ↑→ Vascular calcification↑ → Life span↓				140, 141, 142
Plasma NT-proBNP	↑	E activates BNP, but T inhibition is crucial (also in women)	↓ (-40%)	Inhibit release	41, 143, 144, 145

[a] Estrogen elevates the number of AVP granules in the eminentia mediana [130] at the hypothalamus base whilst shifting body water regulation to lower pOsm-operating points.[117]

1.3. Sex differences in renal arsenic excretion

Several studies have demonstrated a better methylation capacity in women than in men, and the sex differences in the metabolic biotransformation of arsenic seem to play a part in the generally lower arsenic toxicity in females than in males.[3-5] Improved female methylation of As can be partially explained by estrogen-dependent upregulation of the synthesis of choline as a critical cofactor in the generation of SAME, the essential methyl donor in the oxidative methylation of iAs.[4] The lower female consumption of SAME for their reduced creatinine synthesis (App. 3) will further add to this effect. An animal study demonstrated less pronounced decreases in SAME activity after high-dose exposure to arsenate (iAs_V) or arsenite (iAs_{III}) compared to low- or medium-dose exposure in female vs. male rats.[5] Thus, women could dispose of more SAME as an essential cofactor for oxidative methylation of iAs. Apart from the evident advantages in methylation, females also seem to exhibit improved renal antioxidative defense mechanisms due to higher expression of protective enzymes such as eNOS, Metallothionein, Mn-SOD, or Carbon-Anhydrase (App. 3), favoring more efficient oxidative methylation of iAs.[6-8]

Consistent with improved female methylation, several sex-comparative studies reported significantly higher urinary %DMA with lower %iAs and %MMA in women.[3,5,9-13] However, in contrast to the percentage distribution of iAs, MMA, and DMA, no significant differences in covariate dilution-adjusted TWuAs and AsB between males and females were found in a recent large Korean study.[3,14,15]

In this context, the reported male-dominant baseline expression of sodium-coupled PO_4^- cotransporter II (NaPT-II), inhibited by estrogens and facilitating the reabsorption of iAs_V and its subsequent conversion into iAs_{III} in the proximal tubule, appears somewhat counterintuitive since it should theoretically promote lower iAs or %iAs in men.[1,16] The quantitative sex difference in NaPT-II activity, however, is not reflected in sex-diverse serum PO_4^- levels in younger adults when the hormone-related disparities are expected to be highest.[17,18] Serum PO_4^- becomes female-dominant only after menopausal estrogen decline, suggesting that other sex-diverse factors besides NaPT-II, such as testosterone,[19] and the potential activities of different male-dominant tubular PO_4^- transport factors have quantitatively comparable inhibitory effects on PO_4^- reabsorption as estrogen-dependent NaPT-II inhibition has in women (Apps. 1-4). The much steeper decline in estrogen in women compared to testosterone in men, along with favorable female methylation, explains the postmenopausal higher serum phosphate and %DMA, in addition to lower %iAs in women.[17,18]

1.3. Influence of age on renal function and fluid balance

A difficult-to-disentangle causal combination of normal organ senescence, toxic build-up, and degenerative diseases increasingly prevalent with aging, such as diabetes, hypertension, atherosclerosis, or congestive heart disease, induces characteristic changes in the mature kidney.[20-23] Nephrosclerosis comprises four usually concurrent pathohistological findings of the aging kidney: 1. arteriosclerosis, 2. glomerulosclerosis, 3. tubular atrophy, and 4. interstitial fibrosis, with arteriosclerotic fibro-intimal hyperplasia of afferent arterioles being the most primary step of nephrosclerotic degeneration.[21-24] Physiological consequences of these changes are reductions in kidney mass, renal plasma flow (RPF), number of functioning nephrons, available filtration membrane area, and glomerular capillary permeability.[21,25] The resulting decreases in glomerular capillary plasma flow rates and glomerular capillary ultrafiltration coefficients (GCUCs) form the pathophysiological basis for progressively declining glomerular filtration rates (GFRs) in seniors.[21,23]

Glomerular hemodynamics in old age are characterized by reduced vascular resistance of the afferent arterioles in the initial stages of kidney damage and a generally enhanced responsiveness to vasoconstrictive signals.[21] The result is a potentially harmful

increase in glomerular capillary hydrostatic pressure (GCHP), even without systemic hypertension. The concomitant reduction in GCUC and the vasoconstrictive effects of ATII on the afferent arteriole in advanced stages of renal decline prevent an increase in filtration efficiency, as would be expected from increased GCHP alone. Whereas hyperfiltration is commonly seen in the initial stages of renal degeneration,[26] the combined progression of both GCUC reduction and vasoconstriction induces a net impairment of capillary filtration efficacy and GFR.[21]

In more advanced stages of damage, the reduction in GFR is accompanied by limited sulfation and increased permeability to macromolecules of the glomerular basement membrane (GBM). Along with age-degenerative adaptions of podocyte morphology and function, the higher GBM leakiness facilitates the urinary excretion of more significant amounts of albumin and other proteins.[21,27]

The low GFR at birth rises to adult levels by the end of the second year of life and is maintained until the fourth decade before it declines by approximately 5%–10% per decade after the age of 35 years, primarily due to the progressive loss of functioning nephrons.[23] Until the end of the sixth decade, women tend to have lower GFR than men, but these disparities increasingly equalize and even reverse with age due to the faster male decline in mean GFR (1.20 versus 0.96 ml/min per 1.73 m^2 per year).[28] The typically higher blood pressure and earlier development of arteriosclerotic cardiovascular disease in men may account for this phenomenon, as both factors are considered the main drivers of nephrosclerosis.[25,29-32] Other potentially contributing factors are androgen receptor-mediated telomere shortening and apoptosis of tubular cells (App. 3, Sec.1.2) and the superior tissue protection of female kidneys due to estrogen-related inhibitory actions on the RAAS in addition to advantages in methylation and antioxidation.[6,21,23,33,34] By contrast, testosterone tends to increase RAAS activity (Tbl.1a), and experimental estrogen therapy and androgen deprivation mitigated the progression of chronic kidney disease (CKD).[21]

From the onset of GFR decline in the middle of the fourth decade of life until the mid-60s, the reductions in RPF are mainly proportional to GFR decline, translating into almost constant glomerular filtration fractions (FF = ratio GFR/RPF).[21] At higher ages, FF slightly increases due to divergently more substantial drops of RPF compared to GFR, partly due to redistribution of cortical to medullary flow.[21,23]

Apart from the glomerulus, the years lived also leave their mark on the tubular system. Advancing tubulointerstitial fibrosis impairs the tubular secretion and reabsorption of primary urinary components, such as glucose, sodium, other electrolytes, amino acids, hormones, toxic metabolites, and drugs at the proximal and distal tubule.[23] The loop of Henle exhibits a gradual loss of control over salt reabsorption, while in the distal tubule and collecting duct, the decreased sensitivity to aldosterone and AVP results in loss of water and sodium with increased urinary dilution and further reductions of uCR.[35,36]

Renal hemodynamics become maladjusted with aging due to atherosclerosis and alterations in hormonal vasoregulation. Barring the initially age-reduced resistance of glomerular afferent arterioles, other important resistance vessels, such as efferent arterioles or interlobar, arcuate, interlobular arteries, and glomerular afferent arterioles in later stages of CKD, generally exhibit enhanced responses to vasoconstrictors and attenuated reactions to vasodilatory stimuli.[37] This results in an overall increase in total renal vascular resistance and reductions in RPF with aging, particularly in hypertension and albuminuria.[21,23,38,39] These changes are mainly due to the intertwined increased vasoconstrictive activities of AVP and the RAAS (Tbl.1), lowering RPF and GFR in addition to the downregulation of the nitrite oxide (NO) system.[21,40-42] Decreases in NO amplify AVP/RAAS-induced renal vasoconstriction, sodium retention, matrix production, and mesangial fibrosis in seniors.[21,43]

With advancing age, the declining GFR implicates decreases in creatinine clearance (CRC), and lower GFR is associated with lower 24-hour uCR.[44] In spot urine, however, this

association is blurred by the strong dependence of uCR on hydration status, and uCR cannot be considered a sensitive marker of renal function.[45] Neither can the serum CR (sCR) of seniors, who display relatively constant sCR over broad age ranges. Their lower lean muscle mass signifies reduced renal excretory creatinine load, which prevents sCR from rising, irrespective of the CRC reductions already present in lower stages of renal insufficiency.[21]

1.4. Influence of age on renal arsenic excretion

Several studies have investigated the influence of age on the absolute and percentage renal excretion of TWuAs, total uAs (TuAs = iAs + MMA + DMA), and the specified individual TWuAs components.[3,9,46-49] The main problem in interpreting absolute TWuAs values of these studies and their inter-comparability is the conundrum of adequate dilution adjustment. As mentioned, older people produce less creatinine due to reduced lean muscle mass and usually have reduced urine concentrating capacity with lower uCR, specific gravity (SG), and urinary osmolality (Sec.1.4).[1,50] The resulting dilemma is that specific inaccuracies will arise in all classical methods of dilution adjustment as well as in uncorrected urine. While unadjusted values will be lower for older people with comparable exposure due to their higher dilution, the classically corrected readings will be inadequately high, owing to the smaller corrective denominator, be it uCR, SG, or uOsm.[1]

In the Korean study cited above, the arsenic urine levels of 1507 participants were standardized using a modern covariant-adjusted method that considered the influence of age, sex, and BMI on uCR. [3,14,15] These more reliably adjusted results revealed significant positive associations between age and TWuAs or AsB in adults > 18 years. In the age group > 65 years, positive trends were also seen for iAs, MMA, and DMA but failed to reach significance. In another study of 904 participants in Nevada, age was included as an independent covariate in a multiple linear regression model among 15 other factors. It was found to have a significant negative influence on iAs with concurrent positive nonsignificant trends for MMA, DMA, and TuAs.[49] Analyses of the percentage distributions of specified uAs components within the same study confirmed the significant negative effect of age on %iAs, plus a now significantly positive age effect on %DMA. In addition, positive associations were demonstrated between age and methylation capacity. These were found to be highly significant ($p < 0.0001$) for the primary methylation index (PMI = MMA/iAs) and barely non-significant ($p = 0.084$) for the second (SMI = DMA/MMA). The increased methylation of uAs in adults with lower %iAs and higher %DMA is also consistent with previous studies.[9,46]

Apart from age-improved methylation capacity, the reduction in %iAs could be confounded by declines in the proteohormone transmembrane Klotho (m-Kl) with advancing age or age-related CKD (Tbl.2).[51-54] As an essential cofactor of fibroblast growth factor 23 (FGF23), m-KL assists the urinary excretion of iAs_V by inactivating the apical tubular sodium-phosphate cotransporters NaPT-IIa and NaPT-IIc, which also reabsorb iAs_V as their substrate due to its chemical semblance to PO_4^-. The lower activity of m-KL in CKD thus will increase the reabsorption of iAs_V and reduce %iAs. Dehydration, being more frequent in old age, will potentiate this effect via activation of AVP and ATII, which downregulate m-KL with the consequence of further reduced excretion of PO_4^- and iAs_V (Tbl.1). Serum levels of m-KL tend to be female-dominant throughout life,[54-56] while estrogen, testosterone, and sexual hormone binding protein (SHBG) were all positively correlated with serum m-KL also in men.[57] Besides, there is strong evidence for a mediating role of estrogen in the m-KL-induced inhibition of NaPT-II, causing enhanced excretion of PO_4^- and iAs_V.[58,59]

Contrary results with age-associated increased %iAs and decreased %DMA in a smaller study population of an arseniasis-hyperendemic area in Taiwan suggest possible regional differences in the age-dependency of TWuAs composition.[12] These might be attributable to diverse sources and levels of exposure or genetic variance in methylation efficacy.[10] A smaller Bangladeshi study involving children also seems to contradict the notion

Table 2: Effects of age on hormonal and pathological factors influencing renal PO_4^- and iAs excretion.

REGULATORY FACTORS FOR RENAL SECRETION OF PHOSPHATE (PO_4)	NaPT-IIa and -c activity / tubular reabsorption of PO_4 (and iAs_V)	Renal PO_4 - Secretion	Aging-Effect on Factor [d]	Aging-Effect on renal PO_4-Secretion	References
Parathormone (PTH)	↓	↑	↑	↑	147, 148
Fibroblast Growth Factor 23 (FGF23)	↓ m-Klotho (m-KL) acts as essential cofactor for FGF23 [a]	↑	↑ [b]	↓ [b]	52, 53, 149
Transmembrane Klotho (m-KL)	↓	↑	↓ [b]	↓ [b]	51, 52, 53
Angiotensin II (ATII) - elevated in dehydration, volume depletion, Na^+↓, Cl^-↓, blood pressure ↓, CKD, a.o.	↑ ATII blocks m-KL and induces FGF23 resistance [b]	↓	plasma ATII ↓ GFR and RPF response to ATII ↑	(↑)	86, 124, 150, 151
Vasopressin (AVP, ADH) **lower, physiological concentrations** - prevalent Osmoreceptor stimulation - renal V1aR < V2R receptor stimulation - Na+ reabsorption ↑, Na^+- excretion ↓	no significant effect on Pi reabsorption/excretion in rats	–	plasma AVP ↑ renal AVP sensitivity ↓	–	121, 152
Vasopressin (AVP, ADH) **very high concentrations, dehydration** - Baro- and Osmoreceptor stimulation - renal V1aR > V2R receptor stimulation - Na+ reabsorption ↓, Na^+- excretion ↑	↑(?) massive increase in plasma PO_4 independent of PTH and ABP	↓(?)		↑(?)	152, 153
Calcitriol (1α,25(OH)$_2$VitaminD$_3$)	↑ (↓) [c] direct and indirect via PTH↓: ↑ indirect via FGF23↑: ↓	direct ↓ (indirect ↓↑)	direct ↓ (indirect ↓↑)	direct ↑ (indirect ↓↑)	53
Chronic kidney disease (CKD)	↑ due to initial m-KL↓	↓	↑	↓ Serum PO_4↑ in endstage CKD	71
Urinary acidity (pH ↓)	↓ [e]	↑	↓	↑	103, 154
Oxidative Stress	↑ toxic, antioxidative exhaust, inflammatory, aging, ATII-mediated [f]	↓	↑	↓	124, 155

[a] *Membrane Klotho acts as a coreceptor to enhance the binding of the endocrine FGF23 to FGF receptors (FGFRs) through formation of a Klotho/FGFR/FGF23 complex, with subsequent activation of FGF signal transduction, inactivation of NaPT-II and thus enhancement of renal PO_4-secretion.*[53]
[b] *Renal FGF23 resistance due to age- or CKD-related deficiency of m-Klotho leads to elevated FGF23 levels with concomitantly reduced renal phosphate excretion*[124]*. FGF23 is mortality -and morbidity associated.*[149]
[c] *Vitamin D can increase or decrease serum phosphate concentration depending on its balanced effect on parathyroid glands, bone, and intestine.*[53]
[d] *Urinary excretion of PO_4 in old age was found to be diminished in an old study.*[123]
[e] *PO_4^- acts as main urinary buffer and higher urinary acidity (pH↓) reduces tubular PO_4-reabsorption.*
[f] *ATII increases oxidative stress via intracellular formation of reactive oxygen species (ROS) such as the superoxide anion and hydrogen peroxide. It activates several subunits of the membrane-bound multicomponent NAD(P)H oxidase and increases mitochondrial ROS formation.* [206]

of continuous improvement in methylation with age. The authors demonstrated higher mean SMI values concurrent with lower PMI in children than adults. The improved second As-methylation step was hypothesized to facilitate As-excretion in infancy, possibly explaining the absence of typical As-induced skin lesions in children compared to adults of that region.[47]

Additionally, in the advanced aged > 90 years, a reversal of the age-increasing iAs resorption behavior might occur, as can be inferred by the drops in serum PO_4^- levels observed in this age group, which until then tended to increase from the third decade of life.[17] The age-related compromises of renal urinary concentrating ability and the age-limited formation of calcitriol (vitamin D3) involve higher renal losses and reduced intestinal absorption of calcium.[60,61] The resulting increase in plasma PTH will theoretically facilitate renal hyperexcretion of PO_4^- and iAs_V with aging (Tbl.2). In more youthful seniors, these effects appear to be overcompensated by the concomitant age-dependent lack of m-KL.[51-54] In the very old, however, these processes might prevail over the antagonizing age decline of m-KL, leading to the net effect of a de facto increase in PO_4^- and iAs_V excretion in this very advanced age group, whose arsenic excretion has not yet been investigated separately.[17]

1.5. Influence of kidney function on arsenic excretion

The association between CKD and uAs is well known.[45,62,63] To date, several studies have demonstrated significant negative associations between TuAs and eGFR,[45,64,65] and positive associations between TuAs and serum cystatin C,[66] albuminuria, or proteinuria.[63] Furthermore, positive associations exist between TuAs and urinary markers for tubular damage, such as β2 microglobulin and N-acetyl-β-D-glucosaminidase (NAG),[45,65] and CKD mortality rates in various populations consistently rise with TuAs.[45,67,68]

In agreement with most studies on age (Sec. 1.4), several studies on the influence of renal function on uAs excretion also document decreases in %iAs with concurrent elevations of %DMA as GFR declines.[45,69,70] Moreover, there is evidence for impaired excretion of iAs from blood to urine in dysfunctional kidneys, as for a given increase in blood %iAs, the corresponding elevation of urinary %iAs was diminished with reduced GFR.[69]

In one sense, these results are consistent with 'reverse causation,' that is, reduced GFR being a causal factor for the impaired renal excretion of iAs.[70] Subsequent prolonged retention of iAs in blood might facilitate its further methylation and final excretion as DMA. Reverse causation is biochemically substantiated by the apparent downregulation of m-KL and the subsequent higher reabsorption and lower excretion of $PO4^-$ and iAs in CKD (Tbl.2, Sec.1.4).[71] In CKD, renal ATII, an inhibitor of m-KL, is increased due to the release of renin in response to reduced RPF. Conversely, the pharmacological blockade of ATII was found to upregulate the expression of m-KL.[72] Inactivation of m-KL by ATII in CKD thus amplifies the inhibitory influence of m-KL depletion on renal iAs excretion.[73]

In advanced CKD, the effects of m-KL reduction on TuAs composition may become augmented by concurrent tubular dysfunction, inducing further shifts from %iAs to %DMA via disproportional alterations in net excretions of various TuAs constituents.[1]

In theory, the higher %DMA and lower %iAs in CKD could be explained by increased iAs methylation being causative for kidney damage rather than a consequence.[45] In fact, the oxidative methylation of iAs to its main excretion product DMA produces As intermediates substantially more toxic than iAs, such as MMA_{III} or DMA_{III}, which were inconsistently negatively correlated with eGFR.[45,74-77]

2. Study population

The TWuAs-, uCR-, age-, and sex data of the n = 5599 (F 2971, M 2628) unselected spot urinary samples forming the basis for this second part were summarized in the first part of this study.[1] All specimens were obtained between January 2014 and August 2022 and analyzed with ICP-MS at the Institute of Medical Diagnostics (IMD), Berlin, Germany. Unfortunately, more detailed data concerning residency, muscle mass, BMI, dietary and exercise habits, clinical status, kidney function, arsenic exposure, ethnicity, and daytime of sample collection were not available for this retrospective error analysis.

3. Methods/Statistics

For age- and sex-differentiated analyses, all samples with age indication, $uAs_{UC} \leq 500$ µg/L, and uCR < 4.5 g/L (all: n = 5585, F: n = 2967, M: n = 2618) were classified into six age groups (0-10, 11-20, 21-35, 36-50, 51-65, 66-80). For each age group, sex-aggregate and -disaggregate means, medians, SDs, SEs, and ICRs were calculated for uCR and TWuAs. TWuAs was analyzed as uncorrected (uAs_{UC}), CCRC ($uAs_C = uAs_{UC}/uCR$), or standardized to 1 g/L uCR ($uAs_N = uAs_{UC} \times uCR^{-[Ln(uAs_{UC}) + 11.82]/[Ln(uCR) + 18.73]}$) by adopting the V-PFCRC formula inferred in part one of this study.[1] The supplementary Excel file summarizes descriptive statistical data for the individual groups. All three uAs-correction modes and uCR were correlated with years of age for the age band 14-82 years; Pearson correlation coefficients (R) and significance levels (p) were calculated for right-skewed linear and near-normally distributed log data.

The dependence of uAs_{UC}, uAs_C, and uAs_N on uCR was determined by simple power functional regression analyses of sex-aggregate data of the seven age groups and age-aggregate data of both sexes.[1] Exponents *b* and correlation coefficients R of all three uAs results modes were calculated and compared. Male and female samples were standardized

by the uniform sex-aggregated V-PFCRC or by two separately determined, sex-differentiated standardization V-PFCRC formulas. In a second analysis of the identical subgroups, the confounding effects of outliers were reduced by excluding all values above the upper fence of the corresponding box plot. Upper fences (UFs) were determined using the standard formula UF = Q3 + (1.5 × IQR).

To estimate the potentially confounding effects of sex and age on standardization formulas, the analyte-specific log relationship between factor *a* (= uAs_N) and the slope of the assigned power-functional regression curve between uCR and uAs_{UC} (= exponent *b*) was determined for sex-aggregate and - disaggregate data of three different age bands (14-45, 46-58, >58 years) by application of the previously described V-PFRA (see Figs. 2/3 of Part 1).[1]

4. Results

4.1. Effects of sex on uCR and TWuAs

The sex-differential influence of age on uCR, uAs_{UC}, uAs_C, and uAs_N was investigated in seven separate age groups (Fig. 1, App. 5, Supplementary Excel File). Male dominance of uCR and uAs_{UC} was observed in all adult age groups but not in the groups of younger children and adolescents (Fig. 1a/b, App. 5a/b).[1] The sex differences in uCR and uAs_{UC} develop synchronously from young adulthood to their maximum expression in the mid-forties. However, the sex discrepancy of uAs_{UC} is somewhat lagging that of uCR.



Figure 1: Sex-differentiated influence of age on uCR, uAs_{UC}, uAs_C, and uAs_N. All samples with age indication, uAs_{UC} ≤ 500 µg/L, and uCR < 4.5 g/L (n=5585, females n= 2967, males n = 2618) were classified into seven age groups (0-10 y, 11-20 y, 21-35 y, 36-50 y, 51-65 y, 66-80 y, >80 y). The supplementary Excel file gives detailed descriptive statistics for each age group. Means (dots) ± SEs (vertical error bars) were calculated for uCR (a), uAs_{UC} (b), uAs_C (c), and uAs_N (d) in females (red) and males (blue) separately and in sex-aggregate data (green). The sample sizes of the individual subgroups are shown in parentheses next to the data points in graph A. Horizontal age error bars were omitted as age SEs in separate age bands ranged from 0.09 to 0.53 years and thus were too small for visual delimitation from measurement points. Sex ratios of mean values are illustrated in the inlays of Figures A-D. Medians and ICRs of aggregate data in identical subgroups are depicted in App. 5.

Notably, both dilution adjustments, CCRC and, to an even greater extent, V-PFCRC, broadly neutralized the sex difference in uAs_{UC} in all adult age groups, suggesting that these are primarily due to sex differential urinary dilution rather than to any potential sex disparities in arsenic excretion. This could be consistently confirmed in an age-aggregate analysis of the sex differences in all three TWuAs datasets based on n=5400 samples (2493 males, 2907 females) in the age band 14-82 years (App. 6). Like in the age-disaggregate analysis (Fig. 1), the significant male-dominant secretion of uAs_{UC} (m/f ratio 1.51, $p < 0.001$) widely reflects the sex difference in uCR (m/f ratio 1.48, $p > 0.001$). While CCRC reverses male dominance in uAs_C (F > M, $p < 0.011$), V-PFCRC equalizes it to insignificance ($p = 0.191$).

4.2. Effects of age on uCR and TWuAs

By commonly known uCR age dynamics, also in the present study, uCR in both sexes rose sharply from infancy to peak levels in young adulthood, followed by a gradual decay until old age (Fig. 1a, App.5a). In contrast to the age-related decline in uCR, uAs_{UC} steadily increased from infancy to middle age, followed by a tendential drop between 44 and 58 years and a subsequent rebound after 58 years (Fig. 1b, App. 5b). A similar yet more continuous age-dependent increase from early adulthood to senescence was observed in uAs_C (Fig. 1c, App. 5c) and uAs_N (Fig. 1d, App. 5c). The age dependencies summarized in Fig. 1 were also evident in the analyses of corresponding medians and ICRs (App. 5), indicating an extensive overlap of Osmo- and volume-dependent renal excretion mechanisms of uCR and the major TWuAs species. Between the end of puberty and the beginning of the seventh decade of life, the mean sex-aggregated uAs_N increased from 13.4 (age band 11-20, mean age 15.9 y) to 30.5 µg/1 g uCR (age band 66-80, mean age 71.5), and the average annual increase in uAs_N was determined to be 0.28 µg/1 g uCR by linear regression analysis (App. 7).



Figure 2a: Effects of sex and age on log relations between coefficient *a* and exponent *b*. Samples were divided into three age groups, each of which was analyzed for both sexes separately and combined, using the V-PFRA method described in the first part of this study.[1] The three numbers after the dots in the legends refer to 1) the number of creatinine ranges, 2) the number of arsenic ranges, and 3) the sample number per rectangle.[1]



Figure 2b: Effects of sex and age on log relations between coefficient *a*nd exponent *b*. Identical curves from Fig. 2a are grouped by sex.

Pearson analysis of data for all patients between 14 - 72 years and $uAs_{UC} \leq 500$ µg/L revealed weak negative correlations between age and uCR and weak positive correlations between age and all three TWuAs results modes (App. 8).

4.3. Effects of age and sex on V-PFCRC equations

To investigate the potential effects of age and sex on the normalization equation, samples were divided into three age groups, for each of which the log relation between *a* and exponent *b* was calculated sex-aggregated and for both sexes separately (Fig. 2). Young men were found to have substantially higher *b*-values than young women, i.e., the log regression curve for men runs well above that of women. In the middle age group, the male *b*-values exhibit a substantial drop compared to young men. At the same time, those of the women remain unchanged, resulting in an almost complete leveling of sex differences in the middle-aged group. Finally, in the elderly, *b*-values in both sexes rise compared to middle age, with a tendency toward higher values for men but a more minor sex difference than in the young group.

4.4. Validation of V-PFCRC

To determine the relevance of these apparent sex- and age differences in V-PFCRC functions for the validity of uniform normalization in the various sex- or age-specific subgroups, samples were subdivided according to age (Fig. 3a/c, App. 9) or sex (Fig. 3b/d, App. 9). For each group, the residual bias between uCR and TWuAs (uAs_{UC}, $uAs_{C,}$ or uAs_N) was



Figure 3: Sex- and age-differentiated efficacy of standardization. The dependence of uAs_{UC}, uAs_C, and uAs_N on uCR was determined by S-PFRA of various subsets of a total of n=5599 samples (all ages, $uAs_{UC} \leq 500$ µg/L) grouped by age (a/c) and sex (b/d). Equations of the form TWuAs = $a \times uCR^b$ and the corresponding R^2 values were calculated. Exponent *b* and R^2 as measures for the dependency between uCR and uAs are plotted for uAs_{UC} (black bars), uAs_C (dotted bars), and uAs_N (white bars). Numbers in brackets: sample numbers (n)/subset. Male and female samples (b/d) were standardized, with V-PFCRC functions generated either gender aggregated (Fig. 2d) or by two separate, sex-differentiated analyses (indicated as Sex Dif). An analysis of identical subgroups after excluding outliers is illustrated in the App. 9.

determined by S-PFRA. In all age bands and both sexes, a substantial reduction of the dependency of TWuAs from uCR was seen in V-PFCRC results compared to uAs_{UC} or uAs_C. The respective magnitude of exponents b and R^2 decreased in the order $uAs_{UC} > uAs_C >> uAs_N$ in all but the 0–10-year-olds group, featuring only a limited number of highly TWuAs-variable samples. However, when outliers were excluded from the analysis (App. 9), the diminution of the magnitudes of *b* and R_2 to insignificant levels by V-PFCRC could also be demonstrated in the 0-10-year group. The use of separate normalization equations for both sexes (Fig. 3, App. 9, "Sex dif," green bars) yielded only negligibly improved results in females (minor *b* and R_2). At the same time, the outcome in males was worse to a similar degree as the female improvement. It can be concluded that applying the uniform normalization function, determined for both sexes between 14 and 82 years, has widely mitigated the CCRE in all studied subgroups (Fig. 3, App. 5).[1] The apparent age- and sex-specific differences in the relationship between *a* and *b* (Fig. 2a/b) thus do not infer significant systemic misquantifications of uAs_N.

5. Discussion

5.1. Sex differences

The near-synchronous male dominance of uCR and uAs_{UC} in age-aggregate and age-disaggregate analyses suggests extensive commonalities between analytes regarding their hydration-dependent renal excretory mechanisms. The generally lower uCR and uAs_{UC} of females implicate higher numbers and error magnitudes of the overestimated uAs_C values in low uCR samples and reductions of uAs_C underestimations in higher concentrated urines. This results in an inversion of the male-dominant sex bias in $uAs_{UC,}$ with uAs_C being significantly higher in women than men.

The male-dominant sex bias in urinary concentrating ability and uCR can be explained by a complex combination of the sex-differential anatomical, physiological, and hormonal-regulatory factors summarized in Tables 1 and 2 and Appendices 1-4. In contrast, the male increases in urinary concentration, uOsm, tubular sodium reabsorption, and CR are primarily due to the more substantial impacts of the RAAS and vasopressin (AVP) and the weaker influence of AVP-attenuating renal prostaglandins and NT-proBNP in men (Tbl.1). Notably, the complexity of the intricate regulatory network accounting for the sex-divergent normalization equations found in this study (Fig. 2, App) does not seem to constrain the extensive algebraic compensation of the CRCE by the uniform normalization function in either sex. By adequately neutralizing the confounding influence of both variables - uCR and uAs_{UC} - by V-PFCRC, the sex differences of uAs_{UC} and uAs_C could be leveled to insignificance in uAs_N (Fig. 3, Apps. 6,9). Accounting for sex- and age-dependent variations in the log relationships of exponent *b* and factor *a* (Fig. 2a/b) by adopting sex-differentiated equations (Fig. 3b/d, "Sex-Dif") did not yield a demonstrable overall improvement in correction validity compared to the application of the uniform equation. It can be concluded that the non-linear urine dilution mechanisms, whose disregard induces the CCRE, are essentially the same in females and males. Adequate dilution adjustment with V-PFCRC leveled the sex differences in uAs_{UC} and uAs_C, indicating their predominant confounding by differential urinary dilution, mediated by deviating activities of essentially identical osmoregulatory mechanisms merely adjusted by sex-divergent osmolality set points (Tbl.1). Conversely, other sex biases in arsenic metabolism, such as favorable female arsenic methylation and antioxidation, seem to play only a minor role.

5.2. Influence of age

In contrast to the solid positive dependence between uCR and uAs_{UC} in the overall analysis and the age-consistent adult male dominance in both parameters, age was found to affect uCR and $TWuAs_{UC}$ (uAs_{UC}, uAs_C, and uAs_N) in opposite ways (Fig. 1, App. 5).[1] While uCR in both sexes continuously decreases from peak levels in young adulthood, there is a continuous increase in $TWuAs_{UC}$ with advancing age, consistently found in uAs_{UC}, uAs_C, and uAs_N.

Significant age-related increases in TuAs, AsB, and to a lesser extent, MMA and DMA with concurrent tendential reductions in %iAs and possibly iAs have already been described in previous reports.[3,9,46,49] In the present retrospective study, only TWuAs were measured. However, given these previous findings, the methylated uAs components (MMA, DMA, and AsB), which are more abundant in urine, are expected to be the main contributors to the age-related increase in TWuAs. In contrast, a possible contribution of iAs is ambiguous concerning the literature and the various hormonal aging factors acting on the NaPT-II transporters, i.e., on the reabsorption of phosphate and iAs (Tbl.2, Sec.1.4).[3,9,46,49] There is evidence for age reciprocity between TWuAs and %iAs, i.e., the age-related decreases in %iAs and increases in TWuAs (mainly caused by higher methylated species with an uncertain role of iAs) may well be confounded by a common regulatory cause. However, based on previous results and the findings of this study, the most conclusive mechanistic link of both age phenomena appears to be the age-increased baseline actions of AVP (V1)- and ATII, on the one hand inhibiting m-KL and thus enhancing tubular PO_4^-/iAs_V-reabsorption (reducing %iAs) and on the other hand raising FF by limiting RPF more than GFR possibly implicating elevations of TWuAs (Sec.5.3).

While the somewhat unexpected inverse age-dependencies of uCR and all three result modes of TWuAs at first glance seem to contradict a joint transport mechanism,[1,45] it might yet be taken as another piece of evidence for it: age-decline of lean muscle mass and net metabolic turnover signifies reduced production of renally excreted nitrogenous waste products like creatinine. This, in turn, could release common tubular transporters such as MDR1/P-glycoprotein and MATE1 (App. 1) from the excretory burden of uCR, thereby liberating transporter capacity to raise the tubular secretion of TWuAs in middle and older age.[1,45] This effect may be enhanced by age-dependent increases in methylation capacity, resulting in higher proportions of methylated and, thus, more soluble and easily excreted TWuAs species.[3,46,78,79] Interestingly, the increased methylation at higher ages could also be directly causally linked to the declining biosynthesis of creatine and phosphatidylcholine, as these two compounds together require about 80% of the available amount of SAME, the essential methyl donor in arsenic metabolism.[45] In the elderly, SAME could thus be saved and be available in higher concentrations for the methylation of arsenic. In uAs_C and uAs_N, the systemic computational error arising from dividing by too small denominators (uCR) due to age will add to the actual age increments of TWuAs in uAs_{UC}.

A further conclusive contributor to the age increases in TuAs and TWuAs could be higher external and internal As exposure. The generally elevated intestinal permeability of older adults due to dysbiosis, medication, lack of nutrients, and glutathione might increase the external As exposure of seniors by enhancing its absorption rate.[80] At the same time, the age-progressive degradation of bone as the significant natural long-term storage site of As could lead to increased redistribution into the circulation and thus raise the internal exposure to the readily excreted toxin.[81-84]

Independent of the unknown proportional influence of these factors, age is understood as an important positive confounder for TWuAs and TuAs, originating from different mechanisms than the influence of sex. In contrast to the primarily dilution-derived sex disparities, sufficiently compensable by V-PFCR, the effect of age is neither equalized by

CCRC nor by V-PFCRC and should therefore be accounted for in any epidemiological exposure study or norm establishment.

5.3 Pivotal role of osmoregulation in age-/sex-variations of V-PFCRC functions

As demonstrated in Fig. 2, there exists a degree of sex and age disparity in the log relations between coefficient *a* (= standardized uAs_N) and exponent *b*. Steeper slopes with higher *b*-values were found at older ages in both sexes and young men compared to young females and middle-aged males. Given the complexity of sex- and age-specific influences on renal fluid regulation, the possible reasons for these differences between the subgroups of Fig. 2 are manifold (Tbls.1,2; Apps. 1-4). However, there is evidence for a significant role of osmoregulation, as it seems to be influenced similarly to exponent *b* by gender and age. The previously reported sex-specific age dynamics for uOsm exhibited considerable analogy to the *b*-values in Fig. 2 of the present study (App. 10).[85] Similar to exponent *b*, estimated uOsm was higher in young men than in young women, and these sex differences were leveled at middle age due to decreases in male uOsm. In further analogy to exponent *b*, the male-dominant sex difference in uOsm was restored at older ages. The speculation of the sex and age modifications in osmolality set points and its primary actuators, namely, the RAAS (ATII) and AVP (Tab. 1), to incur widely analog alterations in the relationships between coefficients *a* and exponents *b,* stands close. This concept is also consistent with the broad mitigation of the age-related increase in TWuAs after intravenous fluid, suppressing the release and vasopressor actions of AVP/ATII before sample collection (data to be published).

Indeed, there are analogies between the slopes and exponents *b* in Fig. 2 and the age- and sex-variable renal actions of ATII/AVP. There is a general male dominance in the activity of the two closely interrelated hormonal systems, as they are both stimulated by androgens and attenuated by estrogen (Tbl.1). This corresponds to the markedly higher sex discrepancy of *b* at younger ages, i.e., when the opposing sex hormone influences are most prevalent. Declining sex hormone activities toward middle age, being much more pronounced in menopausal women than in men, apparently result in gender alignment of both the renal activities of AVP/RAAS and consequently of uOsm.

In the older age groups, however, an inconsistent discrepancy is notable between *b*-values and uOsm, as in both sexes, *b* rises compared to the middle age group, in contrast to the tending downturns in uOsm. While this could at least partly be due to the somewhat different age group distribution of the two studies, various intrinsic renal aging mechanisms are causing an inelasticity in fluid homeostasis, such as declining renal prostaglandin levels and tubular dysfunction, which may differentially attenuate the vasoconstrictive, salt-and water-retaining effects of ATII/AVP on uOsm and *b*.[86,87] As the vasoconstrictive renal activities of ATII and AVP generally increase with age, the well-known paradoxical deficit in urinary concentrating ability causing lower uOsm in seniors is instead attributable to the intrinsic renal causes.[87,88]

In conclusion, the age- and sex-specific variations of exponent *b* seem to consistently reflect the corresponding vasopressor renal actions of ATII/AVP, regardless of the cause for the increased renal AVP/ATII activities, be it sex-hormone related in the young and renodegenerative in the elderly, and regardless of the age-declining renal concentrating capacity that impairs or even reverses the urinary concentrating effect of ATII/AVP.

However, how could this putative incremental effect of ATII/AVP-mediated renal vasoconstriction on exponent b be mechanistically explained? The closer *b* is to the value of 1, the more constant the mass ratios between TWuAs and uCR with varying hydration/urinary flow rates (UFR). Since *b* values for TWuAs were generally determined to be < 1, TWuAs/uCR mass ratios are reduced with higher urinary concentrations and the correspondingly enhanced activities of ATII and AVP.[1] An increase of exponent b approximating it to the value 1 implies an equilibration of the tubular net secretions of

TWuAs and uCR, i.e., either the net secretion of TWuAs in states of dehydration and elevated ATII/AVP activities increases, its net reabsorption decreases, the net excretion of uCR decreases, or any summation effect of these factors will result in a relative excess excretion of TWuAs over uCR. Since both TWuAs and uCR are freely glomerular filtered and thus proportionally affected by changes in GFR, the variation in their hydration-dependent excretion is necessarily generated by their differential dilution-dependent tubular handling.[1] Any global restriction of tubular relative to glomerular function will therefore align the excretion behaviors of uCR and freely glomerular filtered analytes (here TWuAs), that is, approximate exponent b to the value 1. The concomitant occurrence at more advanced ages of higher TWuAs and impaired tubular function, be it due to elevated ATII/AVP-mediated vasopressor activities or to other intrinsic degenerative factors, indicate a general predominance of tubular TWuAs reabsorption over its secretion under physiological conditions. This notion is also consistent with the positive log-relation of *b* levels and uAs_N and the negative association of CRCE with TWuAs load illustrated in Fig. 3 and Fig. 4c of the first part of this study, as saturation of its tubular reabsorption capacity at higher renal TWuAs loads appears to elevate its net excretion relative to uCR.[1] Limited tubular function, be it due to tubular damage or to lower perfusion of peritubular capillary networks under the influence of strongly pronounced ATII/AVP activities (high baseline + dehydration), is therefore expected to impair reabsorption and thus elevate excretion of TWuAs.

In contrast, the tubular excretory behavior of uCR, which appears mechanistically closely related to the secretion of TWuAs,[1,45] was reported to be affected by ATII/AVP in two opposing ways. While on the one hand, the lower GFR caused by ATII/AVP will increase the tubular secretion of uCR.[89] Conversely, the higher GCHP facilitated by ATII/AVP was associated with more significant tubular reabsorption of CR in healthy subjects.[26,90] The net effect of ATII/AVP on tubular uCR excretion and, thus, TWuAs/uCR ratios will be subject to situational variation.

What are the consequences of these ATII/AVP-dependent alterations in uCR and TWuAs for the dilution-dependent mass ratio of the two urinary analytes? As evidenced by the power-functional relationships between uAs_{UC} and uCR with b-levels usually <1, their mass ratios generally shift toward uCR with rising urinary concentration mediated by the intensified physiological activities of ATII/AVP.[1] That means, in more concentrated urine, uCR is either secreted to a greater or reabsorbed to a lesser extent than TWuAs, as the addition of both possibilities and the predominance of the uCR-increasing component in the case of opposing effects are also conceivable. Furthermore, higher baseline activities of ATII/AVP in younger men and both sexes at older ages may emphasize the uCR-lowering effect of increased GCHP over the enhanced secretion of uCR due to reduced GFR. This could counteract the disparities in tubular handling of uCR and TWuAs, reflected in closer-to-constant mass ratios and higher b-levels within these subgroups.

The effect of lower uCR excretion might be even amplified by disproportionately greater tubular than glomerular functional impairment under the more extreme vasopressor effects of ATII/AVP, generally more potent in efferent than afferent arterioles, implying an increase in GCHP.[26,91,92] While the glomeruli compensate to some extent for the perfusion deficit by increasing FF, the peritubular capillary network supplied by the efferent arteriole is expected to be more profoundly affected by ATII/AVP-induced vasoconstriction of the upstream afferent and efferent arterioles. The resulting revaluation of the glomerular at the expense of tubular contribution to renal TWuAs and uCR excretion will lead to an equalization of the excretion ratio between uCR and TWuAs, as explained above.

Moreover, the mitigating influences of ATII/AVP on m-KL (Tbl.2) could add to these mechanisms, as lower m-KL entails augmented reabsorption and methylation of iAs_V (Sec. 1.4/1.5) with the consequence of increased proportions of methylated TWuAs components, which, like uCR, are more easily excreted.

Indeed, there are many indications of an opposite effect of ATII/AVP on the net tubular excretion of iAs (inhibitory) and oAs/TWuAs (stimulatory), which would consistently explain both lower %iAs and higher TWuAs in seniors and the sex-equal TWuAs excretion despite female advantages in methylation.[3] Males could thus compensate for their methylation drawbacks by enhanced excretion-promoting effects of ATII/AVP on TWuAs.

While these sound theoretical deliberations of a pivotal role of ATII/AVP may conclusively rationalize the sex-age-specific differences in CCRE and the corresponding corrective formulas (Fig. 2), they remain to be consolidated by more established experimental information concerning the tubular handling of iAs and even more so of the methylated uAs species as central components of TWuAs.[45,93]

5.4. Validation, advantages, and limitations of V-PFCRC

The apparent age and sex differences in the V-PFCRC equations proved to exert only a marginal effect on the standardization quality within individual subgroups (Fig. 3, App.9). The most significant limitations of the method are likely to be in children owing to their rapidly changing metabolism and body surface area from infancy through puberty inducing more pronounced age variability in uCR and PO_4^-/iAs-excretion.[17,94] However, even in the relatively small child and adolescent subgroups, a substantial reduction in the residual dependence of the standardized results on uCR was observed after excluding outliers (App.9). This corroborates the significantly improved precision and comparability of the V-PFCRC results in all age groups and both sexes. It stands to reason that by correctly assuming power-functional rather than linear relationships between uAsUC and uCR, a significant source of error in dilution adjustment can be eliminated, regardless of the remaining biases unaccounted for by V-PFCRC. Compared to uncorrected and CCRC values, this could already be demonstrated for simple power-functional corrections incurring significantly improved correlations of standardized TuAs with drinking water exposures.[95]

A significant finding of this study was the confirmation of the age-dependent increase in arsenic excretion, which was evident in both uncorrected (uAs_{UC}) and corrected TWuAs (uAs_C, uAs_N). As such, the TWuAs age increase is genuine and not a mere imputed artifact due to concomitantly decreasing uCR values. Age should therefore be considered for interpreting TWuAs, either by adjusted standard ranges or by an additional standardization step of uAs_N results, e.g., to 50. In contrast, the sex bias does not necessarily require further adjustment since it seems primarily caused by sex disparities of osmoregulatory setpoints being largely accounted for by V-PFCRC (Fig. 1, App.6).

While the advantages of V-PFCRC over CCRC and S-PFCRC are evident, how does it compare with more elaborated covariate-adjusted standardizations, which were reported to provide markedly improved results to the classical models? In general, the V-PFCRC method causally corrects a substantial bias brought about by erroneously assumed linearity in factually non-linear physiological relations. In covariate-adjusted models, this notable misconception is either symptomatically addressed by restricting uCR ranges or ignored within the accepted limits. [1,3,14,96] This confers on V-PFCRC the advantage of dispensing with uCR range restrictions and the associated sample rejects. At the same time, far more reliable, dilution-independent standardized values are achieved in intraindividual and, with minor limitations remaining, also in interindividual comparisons. Fewer sample rejects per se imply resource savings and the disposal of more valid samples will increase the power of any epidemiological study involving urinary biomarkers.

Despite the mathematical adjustment of this major bias by V-PFCRC, residual inaccuracies may result from the unaccounted impact of other biasing factors on uCR and the analyte, primarily of age and lean muscle mass (BMI) and, to a mostly lesser extent, of comorbidities, ethnicity, exercise, nutrition, and daytime of sample collection.[3,14,96]

While accumulative interpretation errors attributable to these unaccounted factors are overall expected to be smaller than CRCE and, like CRCE, will be mostly averaged out in comparable cohorts with sufficient subject numbers, they may still give rise to considerable misinterpretation in exposure analyses of a smaller number of subjects and comparative studies of dissimilar individuals or collectives concerning the covariates mentioned above influencing creatine formation and uCR. In pursuing optimized precision, it may be worthwhile to accommodate these factors additionally. While an age-adjusted V-PFCRC (or an analog variable power-functional correction by SG or uOsm), even if neglecting the confounders of uCR (or SG/uOsm), will provide sufficiently reliable results for most clinical and epidemiological contexts,[95] it may be appropriate to resort to more elaborate covariate-adjusted models or to even integrate V-PFCRC into them depending on the study design. A reasonable, promising future approach could lie in synthesizing more advanced covariate-adjusted standardization plus creatinine covariate adjustment with the V-PFCRC presented in the first part of this study.[1,3,14] Ideally, three sequential standardization steps were adopted in a more sophisticated correction procedure:
1. standardization of uCR (SG, or uOsm) for age, BMI, sex, and other factors by multiple regression covariate adjustment.
2. calculating covariate-uCR adjusted V-PFCRC values for analytes (here, all TWuAs species separately) by adopting V-PFCRC formulas determined using covariate-adjusted uCR.
3. standardization of the obtained V-PFCRC values for age (e.g., for 50 years).

6. Conclusions / Key messages

- The V-PFCRC developed in part I of this study could be further validated by analyzing sex and age influences on CRCE and corrective V-PFCRC formulas. V-PFCRC and analog power-functional adjustments for uOsm or SG substantially improve classical dilution correction by uCR, SG, or uOsm.

- Age- and sex-specific variations in corrective formulas are most likely associated with osmoregulation and renal ATII/AVP. However, they have negligible effects on precision. The just assumption of power-functional relationships between uAsUC and uCR alone generates far more comparable and precise results in both sexes and all ages than CCRC.

- The confounding effect of sex on uAs_{UC} and uAs_{C} is primarily due to dilution. It is thus broadly mitigated by V-PFCRC and does not need further adjustment.

- Significant increases in TWuAs with age are evident in all TWuAs results modes and are not corrected by V-PFCRC. Therefore, the natural age bias in uAs_{N} should be additionally accounted for in normal range determinations and clinical or epidemiological exposure studies.

- Future V-PFCRC approaches could integrate the advantages of multiple linear regression models by correcting for covariate-adjusted uCR.

7. Abbreviations

ABP	Arterial Blood Pressure
As	Arsenic
AsB	Arsenobetaine
ATII	Angiotensin II
AVP	Arginine vasopressin (= Adiuretin, ADH)
CCRC	Conventional Creatinine Correction
CKD	Chronic Kidney Disease
CR	Creatinine
CRC	Creatinine clearance
CRCE	Creatinine Correction Error
DMA	Dimethylarsinic acid
E	Estrogen
FF	Filtration Fraction (FF = ratio GFR/RPF)
FGF23	Fibroblast Growth Factor 23
GBM	Glomerular Basement Membrane
GCHP	Glomerular Capillary Hydrostatic Pressure
GCUC	Glomerular capillary ultrafiltration coefficient
HPA	Hypothalamic-Pituitary Axis
iAs	Inorganic Arsenic (iAs_{III} + iAs_V)
%iAs	Percentage iAs of TuAs
iAs_{III}	Trivalent Arsenite
iAs_V	Pentavalent Arsenate
ICP-MS	Inductively Coupled Plasma Mass Spectrometry
ICR	Interquartile Range
MATE1	Multidrug and Toxin Extrusion Protein 1
m-KL	Proteohormone transmembrane Klotho
MLRM	Multiple Linear Regression Models
MMA	Monomethylarsonic acid
NaPT-II	Sodium-coupled PO_4^- Co-Transporters
NT-proBNP	N-terminal pro B-type Natriuretic Peptide
oAs	Organic Arsenic (Sum of DMA, MMA, AsB, Arseno-sugars, -lipids, and choline)
OCT2	Organic Cation Transporter 2
Osm	Osmolality
P	Progesterone
PFRA	Power Functional Regression Analysis
PGs	Prostaglandins
PO_4^-	Phosphate
PMI	Primary Methylation Index (PMI = MMA/iAs)
RAAS	Renine-Angiotensin-Aldosterone System
RPF	Renal Plasma Flow
SAME	S-Adenosyl-Methionine
sCR	Serum Creatinine
SMI	Secondary Methylation Index (SMI = DMA/MMA).
S-PFCRC	Simple Power Functional Creatinine Correction
S-PFRA	Simple Power Functional Regression Analysis
T	Testosterone
TuAs	Sum of iAs and methylated primary metabolites of iAs (iAs + DMA + MMA)
TWuAs	Total Weight of Urinary Arsenic (all ICP-MS detectable forms, iAs + oAs)
uAs_{UC}	Uncorrected TWuAs

uAs_C	Conventionally Creatinine-corrected TWuAs
uAs_N	TWuAs, normalized to 1 g/L uCR by V-PFCRC
uCR	Urinary Creatinine
UFR	Urinary Flow Rate
uOsm	Urinary Osmolality
V-PFCRC	Variable Power Functional Creatinine Correction
V-PFRA	Variable Power Functional Regression Analysis

8. Acknowledgements

Dr. Katrin Huesker, department manager of Special Immunology, IMD Berlin, is thanked for providing anonymized spot urine data.
Mischa Katz GE is thanked for his time-saving help in data preparation and programming.

9. Author contribution

The idea, basic concept, procurement, data preparation and evaluation, literature research, developing corrective functions, graphs, tables, labels, writing, and submitting the paper.

10. Conflict of Interest

No conflict of interest is known to me.

11. Ethics

The study was exempt from ethical approval by the Ethics Committee of Northwest and Central Switzerland (EKNZ), 4056 Basel, based on retrospective analysis of anonymized data without clinical information other than urinary creatinine/TWuAs, age in years, sex, and date of exam. The purpose was methodological quality improvement only. No pharmacological or other medical intervention, no risk for physical or psychological harm, identifiability, or breach of confidentiality for any subject involved.

12. Funding

The study was not funded.

13. References

1) Carmine TC. Non-Linear Creatinine Dilution Adjustment of Exemplary Urine Arsenic – Part I: Curving the Lines. 2023. medRxiv 2023.02.09.23285582 doi: https://doi.org/10.1101/2023.02.09.23285582.

2) Brosnan JT, da Silva RP, Brosnan ME. The metabolic burden of creatine synthesis. Amino Acids. 2011 May;40(5):1325-31. doi: 10.1007/s00726-011-0853-y. Epub 2011 Mar 9. PMID: 21387089.

3) Choi JW, Song YC, Cheong NY, Lee K, Kim S, Lee KM, Ji K, Shin MY, Kim S. Concentrations of blood and urinary arsenic species and their characteristics in general Korean population. Environ Res. 2022 Nov;214(Pt 2):113846. doi: 10.1016/j.envres.2022.113846. Epub 2022 Jul 9. PMID: 35820651.

4) Fischer LM, da Costa KA, Kwock L, Galanko J, Zeisel SH. Dietary choline requirements of women: effects of estrogen and genetic variation. Am J Clin Nutr. 2010 Nov;92(5):1113-9. doi: 10.3945/ajcn.2010.30064. Epub 2010 Sep 22. PMID: 20861172; PMCID: PMC2954445.

5) Muhetaer M, Yang M, Xia R, Lai Y, Wu J. Gender difference in arsenic biotransformation is an important metabolic basis for arsenic toxicity. BMC Pharmacol Toxicol. 2022 Feb 28;23(1):15. doi: 10.1186/s40360-022-00554-w. PMID: 35227329; PMCID: PMC8883647.

6) Sabolić I, Asif AR, Budach WE, Wanke C, Bahn A, Burckhardt G. Gender differences in kidney function. Pflugers Arch. 2007 Dec;455(3):397-429. doi: 10.1007/s00424-007-0308-1. Epub 2007 Jul 19. PMID: 17638010.

7) Dubey RK, Jackson EK. Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. Am J Physiol Renal Physiol. 2001 Mar;280(3): 365-88. doi: 10.1152/ajprenal.2001.280.3.F365. PMID: 11181399.

8) Monti DM, De Simone G, Langella E, Supuran CT, Di Fiore A, Monti SM. Insights into the role of reactive sulfhydryl groups of Carbonic Anhydrase III and VII during oxidative damage. J Enzyme Inhib Med Chem. 2017 Dec;32(1):5-12. doi: 10.1080/14756366.2016.1225046. Epub 2016 Oct 21. PMID: 27766895; PMCID: PMC6010095.

9) Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE. Methylation study of a population environmentally exposed to arsenic in drinking water. Environ Health Perspect. 1996 Jun;104(6):620-28. doi: 10.1289/ehp.96104620. PMID: 8793350; PMCID: PMC1469390.

10) García-Alvarado FJ, Neri-Meléndez H, Pérez Armendáriz L, Rivera Guillen M. Polimorfismos del gen Arsénico 3 Metiltransferasa (As3MT) y la eficiencia urinaria del metabolismo del arsénico en una población del norte de México [Polymorphisms of the Arsenite Methyltransferase (As3MT) gene and urinary efficiency of arsenic metabolism in a population in northern Mexico]. Rev Peru Med Exp Salud Publica. 2018 Jan-Mar;35(1):72-76. Spanish. doi: 10.17843/rpmesp.2018.351.3565. PMID: 29924282.

11) Torres-Sánchez L, López-Carrillo L, Rosado JL, Rodriguez VM, Vera-Aguilar E, Kordas K, García-Vargas GG, Cebrian ME. Sex differences in the reduction of arsenic methylation capacity as a function of urinary total and inorganic arsenic in Mexican children. Environ Res. 2016 Nov;151:38-43. doi: 10.1016/j.envres.2016.07.020. Epub 2016 Jul 21. PMID: 27450997.

12) Hsueh YM, Huang YL, Huang CC, Wu WL, Chen HM, Yang MH, Lue LC, Chen CJ. Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J Toxicol Environ Health A. 1998 Jul 24;54(6):431-44. doi: 10.1080/009841098158728. PMID: 9661909.

13) Loffredo CA, Aposhian HV, Cebrian ME, Yamauchi H, Silbergeld EK. Variability in human metabolism of arsenic. Environ Res. 2003 Jun;92(2):85-91. doi: 10.1016/s0013-9351(02)00081-6. PMID: 12854687.

14) O'Brien KM, Upson K, Cook NR, Weinberg CR. Environmental Chemicals in Urine and Blood: Improving Methods for Creatinine and Lipid Adjustment. Environ Health Perspect. 2016 Feb;124(2):220-7. doi: 10.1289/ehp.1509693. Epub 2015 Jul 24. PMID: 26219104; PMCID: PMC4749084.
Covariate-adjusted standardization method available in:
http://www.niehs.nih.gov/research/resources/ software/biostatistics/covariate/index.cfm

15) Bulka CM, Mabila SL, Lash JP, Turyk ME, Argos M. Arsenic and Obesity: A Comparison of Urine Dilution Adjustment Methods. Environ Health Perspect. 2017 Aug 28;125(8):087020. doi: 10.1289/EHP1202. PMID: 28858828; PMCID: PMC5783631.

16) Veiras LC, Girardi ACC, Curry J, Pei L, Ralph DL, et.al. Sexual Dimorphic Pattern of Renal Transporters and Electrolyte Homeostasis. J Am Soc Nephrol. 2017 Dec;28(12):3504-3517. doi: 10.1681/ASN.2017030295. Epub 2017 Aug 3. PMID: 28774999; PMCID: PMC5698077.

17) Koek WNH, Campos-Obando N, van der Eerden BCJ, et.al. Age-dependent sex differences in calcium and phosphate homeostasis. Endocr Connect. 2021 Mar;10(3):273-282. doi: 10.1530/EC-20-0509. PMID: 33543729; PMCID: PMC8052581.

18) Cirillo M, Bilancio G, Marcarelli F. Ageing and changes in phosphate transport: clinical implications. J Nephrol. 2010 Nov-Dec;23 Suppl 16:S152-7. PMID: 21170873.

19) Meng J, Ohlsson C, Laughlin GA, Chonchol M, Wassel CL, Ljunggren O, Karlsson MK, Mellstrom D, Orwoll ES, Barrett-Connor E, Ix JH; Osteoporotic Fractures in Men (MrOs) Study Group. Associations of estradiol and testosterone with serum phosphorus in older men: the Osteoporotic Fractures in Men study. Kidney Int. 2010 Aug;78(4):415-22. doi: 10.1038/ki.2010.161. Epub 2010 Jun 9. PMID: 20531458; PMCID: PMC3787687.

20) Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976 Mar;31(2):155-63. doi: 10.1093/geronj/31.2.155. PMID: 1249404.

21) Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010 Jul;17(4):302-7. doi: 10.1053/j.ackd.2010.05.002. PMID: 20610357; PMCID: PMC2901622.

22) Schmitt R, Melk A. Molecular mechanisms of renal aging. Kidney Int. 2017 Sep;92(3):569-579. doi: 10.1016/j.kint.2017.02.036. Epub 2017 Jul 18. PMID: 28729036.

23) Glassock RJ, Rule AD. The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney Int. 2012 Aug;82(3):270-7. doi: 10.1038/ki.2012.65. Epub 2012 Mar 21. PMID: 22437416; PMCID: PMC3513938.

24) Martin JE, Sheaff MT. Renal ageing. J Pathol. 2007 Jan;211(2):198-205. doi: 10.1002/path.2111. PMID: 17200944.

25) Hoang K, Tan JC, Derby G, Blouch KL, Masek M, Ma I, Lemley KV, Myers BD. Determinants of glomerular hypofiltration in aging humans. Kidney Int. 2003 Oct;64(4):1417-24. doi: 10.1046/j.1523-1755.2003.00207.x. PMID: 12969161.

26) Torres VE. Vasopressin in chronic kidney disease: an elephant in the room? Kidney Int. 2009 Nov;76(9):925-8. doi: 10.1038/ki.2009.325. PMID: 19829311; PMCID: PMC2925670.

27) Wiggins JE, Goyal M, Sanden SK, Wharram BL, Shedden KA, Misek DE, Kuick RD, Wiggins RC. Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol. 2005 Oct;16(10):2953-66. doi: 10.1681/ASN.2005050488. Epub 2005 Aug 24. PMID: 16120818.

28) Melsom T, Norvik JV, Enoksen IT, Stefansson V, Mathisen UD, Fuskevåg OM, Jenssen TG, Solbu MD, Eriksen BO. Sex Differences in Age-Related Loss of Kidney Function. J Am Soc Nephrol. 2022 Oct;33(10):1891-1902. doi: 10.1681/ASN.2022030323. Epub 2022 Aug 17. PMID: 35977806; PMCID: PMC9528336.

29) Maas AH, Appelman YE. Gender differences in coronary heart disease. Neth Heart J. 2010 Dec;18(12):598-602. doi: 10.1007/s12471-010-0841-y. PMID: 21301622; PMCID: PMC3018605.

30) Towfighi A, Zheng L, Ovbiagele B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med. 2009 Oct 26;169(19):1762-6. doi: 10.1001/archinternmed.2009.318. PMID: 19858433.

31) Man JJ, Beckman JA, Jaffe IZ. Sex as a Biological Variable in Atherosclerosis. Circ Res. 2020 Apr 24;126(9):1297-1319. doi: 10.1161/CIRCRESAHA.120.315930. Epub 2020 Apr 23. PMID: 32324497; PMCID: PMC7185045.

32) Vakhtangadze T, Singh Tak R, Singh U, Baig MS, Bezsonov E. Gender Differences in Atherosclerotic Vascular Disease: From Lipids to Clinical Outcomes. Front Cardiovasc Med. 2021 Jun 28;8:707889. doi: 10.3389/fcvm.2021.707889. PMID: 34262956; PMCID: PMC8273377.

33) Berg UB. Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transplant. 2006 Sep;21(9):2577-82. doi: 10.1093/ndt/gfl227. Epub 2006 May 23. PMID: 16720595.

34) Melsom T, Norvik JV, Enoksen IT, Stefansson V, Mathisen UD, Fuskevåg OM, Jenssen TG, Solbu MD, Eriksen BO. Sex Differences in Age-Related Loss of Kidney Function. J Am Soc Nephrol. 2022 Oct;33(10):1891-1902. doi: 10.1681/ASN.2022030323. Epub 2022 Aug 17. PMID: 35977806; PMCID: PMC9528336.

35) Musso CG, Macías-Núñez JF. Dysfunction of the thick loop of Henle and senescence: from molecular biology to clinical geriatrics. Int Urol Nephrol. 2011 Mar;43(1):249-52. doi: 10.1007/s11255-010-9783-y. Epub 2010 Nov 12. PMID: 21072593.

36) O'Sullivan ED, Hughes J, Ferenbach DA. Renal Aging: Causes and Consequences. J Am Soc Nephrol. 2017 Feb;28(2):407-20. doi: 10.1681/ASN.2015121308. Epub 2016 Nov 15. PMID: 28143966; PMCID: PMC5280008.

37) Chade AR. Renal vascular structure and rarefaction. Compr Physiol. 2013 Apr;3(2):817-31. doi: 10.1002/cphy.c120012. PMID: 23720331; PMCID: PMC3936257.

38) Clark CM, Monahan KD, Drew RC. Aging augments renal vasoconstrictor response to orthostatic stress in humans. Am J Physiol Regul Integr Comp Physiol. 2015 Dec 15;309(12):R1474-8. doi: 10.1152/ajpregu.00291.2015. Epub 2015 Oct 14. PMID: 26468259; PMCID: PMC4698412.

39) Patel HM, Mast JL, Sinoway LI, Muller MD. Effect of healthy aging on renal vascular responses to local cooling and apnea. J Appl Physiol (1985). 2013 Jul 1;115(1):90-6. doi: 10.1152/japplphysiol.00089.2013. Epub 2013 May 2. PMID: 23640587; PMCID: PMC3727011.

40) Medina D, Mehay D, Arnold AC. Sex differences in cardiovascular actions of the renin-angiotensin system. Clin Auton Res. 2020 Oct;30(5):393-408. doi: 10.1007/s10286-020-00720-2. Epub 2020 Aug 29. PMID: 32860555; PMCID: PMC7572792.

41) Komukai K, Mochizuki S, Yoshimura M. Gender and the renin-angiotensin-aldosterone system. Fundam Clin Pharmacol. 2010 Dec;24(6):687-98. doi: 10.1111/j.1472-8206.2010.00854.x. PMID: 20608988.

42) Usberti M, Federico S, Di Minno G, Ungaro B, Ardillo G, Pecoraro C, Cianciaruso B, Cerbone AM, Cirillo F, Pannain M, et al. Effects of angiotensin II on plasma ADH, prostaglandin synthesis, and water excretion in normal humans. Am J Physiol. 1985 Feb;248(2 Pt 2):254-59. doi: 10.1152/ajprenal.1985.248.2.F254. PMID: 3881995.

43) Baylis C. Sexual dimorphism in the aging kidney: differences in the nitric oxide system. Nat Rev Nephrol. 2009 Jul;5(7):384-96. doi: 10.1038/nrneph.2009.90. Epub 2009 Jun 2. PMID: 19488070.

44) Rule AD, Bailey KR, Lieske JC, Peyser PA, Turner ST. Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease. Kidney Int. 2013 Jun;83(6):1169-76. doi: 10.1038/ki.2013.7. Epub 2013 Feb 20. Erratum in: Kidney Int. 2013 Aug;84(2):419. PMID: 23423253; PMCID: PMC3661736.

45) Peters BA, Hall MN, Liu X, Neugut YD, Pilsner JR, Levy D, et al. (2014) Creatinine, Arsenic Metabolism, and Renal Function in an Arsenic-Exposed Population in Bangladesh. PLoS ONE 9(12): e113760. https://doi.org/10.1371/journal.pone.0113760.

46) Kile ML, Hoffman E, Hsueh Y-M, Afroz S, Quamruzzaman Q, Rahman M, Mahiuddin G, Ryan LM, and Christiani DC. Variability in Biomarkers of Arsenic Exposure and Metabolism in Adults over Time. Environmental Health Perspectives 117 (2009):455-60. DOI:10.1289/ehp.11251. PMID: 15577230.

47) Chowdhury UK, Rahman MM, Sengupta MK, Lodh D, Chanda CR, Roy S, Quamruzzaman Q, Tokunaga H, Ando M, Chakraborti D. Pattern of excretion of arsenic compounds [arsenite, arsenate, MMA(V), DMA(V)] in urine of children compared to adults from an arsenic exposed area in Bangladesh. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2003 Jan;38(1):87-113. doi: 10.1081/ese-120016883. PMID: 12635821.

48) Bae HS, Ryu DY, Choi BS, Park JD. Urinary Arsenic Concentrations and their Associated Factors in Korean Adults. Toxicol. Res. 2013;29(2): 137-42. doi: 10.5487/TR.2013.29.2.137.

49) Hudgens EE, Drobna Z, He B, Le XC, Styblo M, Rogers J, Thomas DJ. Biological and behavioral factors modify urinary arsenic metabolic profiles in a U.S. population. Environ Health. 2016 May 26;15(1):62. doi: 10.1186/s12940-016-0144-x. PMID: 27230915; PMCID: PMC4880853.

50) Moriguchi J, Ezaki T, Tsukahara T, Furuki K, Fukui Y, Okamoto S, Ukai H, Sakurai H, Shimbo S, Ikeda M. Comparative evaluation of four urinary tubular dysfunction markers, with special references to the effects of aging and correction for creatinine concentration. Toxicol Lett. 2003 Aug 28;143(3):279-90. doi: 10.1016/s0378-4274(03)00181-4. PMID: 12849688.

51) Buchanan S, Combet E, Stenvinkel P, Shiels PG. Klotho, Aging, and the Failing Kidney. Front Endocrinol (Lausanne). 2020 Aug 27;11:560. doi: 10.3389/fendo.2020.00560. PMID: 32982966; PMCID: PMC7481361.

52) Tan SJ, Smith ER, Hewitson TD, Holt SG, Toussaint ND. The importance of klotho in phosphate metabolism and kidney disease. Nephrology (Carlton). 2014 Aug;19(8):439-49. doi: 10.1111/nep.12268. PMID: 24750549.

53) Torres PA, De Brauwere DP. Three feedback loops precisely regulating serum phosphate concentration. Kidney Int. 2011 Sep;80(5):443-5. doi: 10.1038/ki.2011.146. PMID: 21841832.

54) Behringer V, Stevens JMG, Deschner T, Sonnweber R, Hohmann G. Aging and sex affect soluble alpha klotho levels in bonobos and chimpanzees. Front Zool. 2018 Sep 19;15:35. doi: 10.1186/s12983-018-0282-9. PMID: 30250491; PMCID: PMC6146871.

55) Pedersen L, Pedersen SM, Brasen CL, Rasmussen LM. Soluble serum Klotho levels in healthy subjects. Comparison of two different immunoassays. Clin Biochem. 2013 Aug;46(12):1079-1083. doi: 10.1016/j.clinbiochem.2013.05.046. Epub 2013 May 23. PMID: 23707222.

56) Gkentzi D, Efthymiadou A, Kritikou D, Chrysis D. Fibroblast growth factor 23 and Klotho serum levels in healthy children. Bone. 2014 Sep;66:8-14. doi: 10.1016/j.bone.2014.05.012. Epub 2014 May 29. PMID: 24880094.

57) Zhang Z, Qiu S, Huang X, Jin K, Zhou X, Lin T, Zou X, Yang Q, Yang L, Wei Q. Association between testosterone and serum soluble α-klotho in U.S. males: a cross-sectional study. BMC Geriatr. 2022 Jul 11;22(1):570. doi: 10.1186/s12877-022-03265-3. PMID: 35820842; PMCID: PMC9275159.

58) Ix JH, Chonchol M, Laughlin GA, Shlipak MG, Whooley MA. Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study. Am J Kidney Dis. 2011 Nov;58(5):737-45.
doi: 10.1053/j.ajkd.2011.06.011. Epub 2011 Aug 19. PMID: 21855188; PMCID: PMC3199317.

59) Chen K, Sun Z. Estrogen inhibits renal Na-Pi Co-transporters and improves klotho deficiency-induced acute heart failure. Redox Biol. 2021 Nov;47:102173.
doi: 10.1016/j.redox.2021.102173. Epub 2021 Oct 18. PMID: 34678656;
PMCID: PMC8577443.

60) Charbonneau A, Leclerc M, Brunette MG. Effect of angiotensin II on calcium reabsorption by the luminal membranes of the nephron. Am J Physiol Endocrinol Metab. 2001 Jun;280(6):E928-36. doi: 10.1152/ajpendo.2001.280.6.E928. PMID: 11350774.

61) Hanouna G, Haymann JP, Baud L, Letavernier E. Vasopressin regulates renal calcium excretion in humans. Physiol Rep. 2015 Nov;3(11):e12562. doi: 10.14814/phy2.12562.
PMID: 26620256; PMCID: PMC4673622.

62) Orr SE, Bridges CC. Chronic Kidney Disease and Exposure to Nephrotoxic Metals. International Journal of Molecular Sciences. 2017; 18(5):1039.
https://doi.org/10.3390/ijms18051039.

63) Zheng L, Kuo CC, Fadrowski J, Agnew J, Weaver VM, Navas-Acien A. Arsenic and Chronic Kidney Disease: A Systematic Review. Curr Environ Health Rep. 2014 Sep 1;1(3):192-207.
doi: 10.1007/s40572-014-0024-x. PMID: 25221743; PMCID: PMC4159179.

64) Hsueh YM, Chung CJ, Shiue HS, et al. Urinary arsenic species and CKD in a Taiwanese population: a case-control study. Am J Kidney Dis. 2009 Nov;54(5):859-70.
doi: 10.1053/j.ajkd.2009.06.016. Epub 2009 Aug 14. PMID: 19682779.

65) Chen JW, Chen HY, Li WF, Liou SH, Chen CJ, Wu JH, Wang SL. The association between total urinary arsenic concentration and renal dysfunction in a community-based population from central Taiwan. Chemosphere. 2011 Jun;84(1):17-24.
doi: 10.1016/j.chemosphere.2011.02.091. Epub 2011 Apr 1. PMID: 21458841.

66) Poręba R, Gać P, Poręba M, Antonowicz-Juchniewicz J, Andrzejak R. Relation between occupational exposure to lead, cadmium, arsenic and concentration of cystatin C. Toxicology. 2011 May 10;283(2-3):88-95. doi: 10.1016/j.tox.2011.02.008. Epub 2011 Feb 26. PMID: 21356263.

67) Meliker JR, Wahl RL, Cameron LL, Nriagu JO. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ Health. 2007 Feb 2;6:4. doi: 10.1186/1476-069X-6-4. PMID: 17274811; PMCID: PMC1797014.

68) Tsai SM, Wang TN, Ko YC. Mortality for certain diseases in areas with high levels of arsenic in drinking water. Arch Environ Health. 1999 May-Jun;54(3):186-93.
doi: 10.1080/00039899909602258. PMID: 10444040.

69) Peters BA, Hall MN, Liu X, Slavkovich V, Ilievski V, Alam S, Siddique AB, Islam T, Graziano JH, Gamble MV. Renal function is associated with indicators of arsenic methylation capacity in Bangladeshi adults. Environ Res. 2015 Nov;143(Pt A):123-30. doi: 10.1016/j.envres.2015.10.001. Epub 2015 Oct 19. PMID: 26476787; PMCID: PMC4740972.

70) Zheng LY, Umans JG, Yeh F, Francesconi KA, Goessler W, Silbergeld EK, Bandeen-Roche K, Guallar E, Howard BV, Weaver VM, Navas-Acien A. The association of urine arsenic with prevalent and incident chronic kidney disease: evidence from the Strong Heart Study. Epidemiology. 2015 Jul;26(4):601-12. doi: 10.1097/EDE.0000000000000313. PMID: 25929811; PMCID: PMC4844343.

71) Zou D, Wu W, He Y, Ma S, Gao J. The role of klotho in chronic kidney disease. BMC Nephrol. 2018 Oct 22;19(1):285. doi: 10.1186/s12882-018-1094-z. PMID: 30348110; PMCID: PMC6198535.

72) Yoon HE, Ghee JY, Piao S, Song JH, Han DH, Kim S, Ohashi N, Kobori H, Kuro-o M, Yang CW. Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy. Nephrol Dial Transplant. 2011 Mar;26(3):800-13. doi: 10.1093/ndt/gfq537. Epub 2010 Sep 2. PMID: 20813770; PMCID: PMC3108350.

73) Laffer CL, Elijovich F, Sahinoz M, Pitzer A, Kirabo A. New Insights Into the Renin-Angiotensin System in Chronic Kidney Disease. Circ Res. 2020 Aug 14;127(5):607-609. doi: 10.1161/CIRCRESAHA.120.317624. Epub 2020 Aug 13. PMID: 32790525; PMCID: PMC7430039.

74) Petrick JS, Ayala-Fierro F, Cullen WR, Carter DE, Vasken Aposhian H. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol. 2000 Mar 1;163(2):203-7. doi: 10.1006/taap.1999.8872. PMID: 10698679.

75) Vahter M, Concha G. Role of Metabolism in Arsenic Toxicity. Pharmacology & Toxicology. 2001;89:1-5. https://doi.org/10.1111/j.1600-0773.2001.890101.x.

76) Stýblo M, Drobná Z, Jaspers I, Lin S, Thomas DJ. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ Health Perspect. 2002 Oct;110 Suppl 5(Suppl 5):767-71. doi: 10.1289/ehp.110-1241242. PMID: 12426129; PMCID: PMC1241242.

77) Steinmaus C, Yuan Y, Kalman D, Rey OA, Skibola CF, Dauphine D, Basu A, Porter KE, Hubbard A, Bates MN, Smith MT, Smith AH. Individual differences in arsenic metabolism and lung cancer in a case-control study in Cordoba, Argentina. Toxicol Appl Pharmacol. 2010 Sep 1;247(2):138-45. doi: 10.1016/j.taap.2010.06.006. Epub 2010 Jun 17. PMID: 20600216; PMCID: PMC3849353.

78) Jansen RJ, Argos M, Tong L, Li J, Rakibuz-Zaman M, Islam MT, Slavkovich V, Ahmed A, Navas-Acien A, Parvez F, Chen Y, Gamble MV, Graziano JH, Pierce BL, Ahsan H. Determinants and Consequences of Arsenic Metabolism Efficiency among 4,794 Individuals: Demographics, Lifestyle, Genetics, and Toxicity. Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):381-90. doi:10.1158/1055-9965.EPI-15-0718. Epub 2015 Dec 16. PMID: 26677206; PMCID: PMC4767610.

79) Tseng CH. A review on environmental factors regulating arsenic methylation in humans. Toxicol Appl Pharmacol. 2009 Mar 15;235(3):338-50.
doi: 10.1016/j.taap.2008.12.016. Epub 2008 Dec 30. PMID: 19168087.

80) Qi Y, Goel R, Kim S, Richards EM, Carter CS, Pepine CJ, Raizada MK, Buford TW. Intestinal Permeability Biomarker Zonulin is Elevated in Healthy Aging. J Am Med Dir Assoc. 2017 Sep 1;18(9):810.e1-810.e4. doi: 10.1016/j.jamda.2017.05.018. Epub 2017 Jul 1. PMID: 28676292; PMCID: PMC5581307.

81) Fowler BA, Selene CH, Chou J, Jones RL, Costa M, Chien-Jen Chen. Chapter 3 - Arsenic. Editor(s): Gunnar F. Nordberg, Max Costa. Handbook on the Toxicology of Metals (Fifth Edition), Vol 2, Academic Press, 2022, Pages 41-89, ISBN 9780128229460, https://doi.org/10.1016/B978-0-12-822946-0.00037-4.

82) Chang LZ, Sheng S, Zhe Z, Xiaoxiao S, Qing J. Study on the relationship between age and the concentrations of heavy metal elements in human bone. Ann Transl Med. 2018;6(16):320. doi: 10.21037/atm.2018.08.09. PMCID: PMC6186975; PMID: 30363972.

83) Ayla Akbal, Hınç Yılmaz & Engin Tutkun (2014) Arsenic exposure associated with decreased bone mineralization in male, The Aging Male, 17:4, 256-258.
doi: 10.3109/13685538.2013.819326.

84) Chang LZ, Sheng S, Zhe Z, Xiaoxiao S, Qing J. Study on the relationship between age and the concentrations of heavy metal elements in human bone. Ann Transl Med. 2018;6(16):320. doi: 10.21037/atm.2018.08.09. PMCID: PMC6186975; PMID: 30363972.

85) Perucca J, Bouby N, Valeix P, Bankir L. Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R700-5. doi: 10.1152/ajpregu.00500.2006. Epub 2006 Sep 21. PMID: 16990487.

86) Yoon HE, Choi BS. The renin-angiotensin system and aging in the kidney. Korean J Intern Med. 2014 May;29(3):291-5. doi: 10.3904/kjim.2014.29.3.291. Epub 2014 Apr 29. PMID: 24851061; PMCID: PMC4028516.

87) Phillips PA, Rolls BJ, Ledingham JG, Forsling ML, Morton JJ, Crowe MJ, Wollner L. Reduced thirst after water deprivation in healthy elderly men. N Engl J Med. 1984 Sep 20;311(12):753-9. doi: 10.1056/NEJM198409203111202. PMID: 6472364.

88) Birder LA, Wolf-Johnston AS, Jackson EK, Wein AJ, Dmochowski R. Aging increases the expression of vasopressin receptors in both the kidney and urinary bladder. Neurourol Urodyn. 2019 Jan;38(1):393-397. doi: 10.1002/nau.23830. Epub 2018 Oct 12.
PMID: 30311671; PMCID: PMC9839378.

89) Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985 Nov;28(5):830-8.
doi: 10.1038/ki.1985.205. PMID: 2418254.

90) Tsuda A, Ishimura E, Machiba Y, Uedono H, Nakatani S, Mori K, Uchida J, Emoto M: Increased Glomerular Hydrostatic Pressure is Associated with Tubular Creatinine Reabsorption in Healthy Subjects. Kidney Blood Press Res 2020;45:996-1008. doi:10.1159/000510838.

91) Dalal R, Bruss ZS, Sehdev JS. Physiology, Renal Blood Flow and Filtration. [Updated 2022 Jul 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482248/.

92) Denton KM, Fennessy PA, Alcorn D, Anderson WP. Morphometric analysis of the actions of angiotensin II on renal arterioles and glomeruli. Am J Physiol. 1992 Mar; 262(3 Pt 2):F367-72. doi: 10.1152/ajprenal.1992.262.3.F367. PMID: 1558155.

93) Ginsburg JM. The renal mechanism for excretion and transformation of arsenic in the dog. Am J Physiol. 1965 May;208:832-40. doi: 10.1152/ajplegacy.1965.208.5.832. PMID: 14286849.

94) Mage DT, Allen RH, Gondy G, Smith W, Barr DB, Needham LL. Estimating pesticide dose from urinary pesticide concentration data by creatinine correction in the Third National Health and Nutrition Examination Survey (NHANES-III). J Expo Anal Environ Epidemiol. 2004 Nov;14(6):457-65. doi: 10.1038/sj.jea.7500343. PMID: 15367927.

95) Middleton DRS, Watts MJ, Polya DA. A comparative assessment of dilution correction methods for spot urinary analyte concentrations in a UK population exposed to arsenic in drinking water. *Environ Int.* 2019 Sep; **130**: 104721. doi: 10.1016/j.envint.2019.03.069. Epub 2019 Jun 14. PMID: 31207477; PMCID: PMC6686075.

96) Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environmental health perspectives. 2005;113:192-200. doi: 10.1289/ehp.7337.

97) Claybaugh JR, Sato AK, Crosswhite LK, Hassell LH. Effects of time of day, gender, and menstrual cycle phase on the human response to a water load. Am J Physiol Regul Integr Comp Physiol. 2000 Sep;279(3):R966-73. doi: 10.1152/ajpregu.2000.279.3.R966. PMID: 10956255.

98) Oparil S, Ehrlich EN, Lindheimer MD. Effect of progesterone on renal sodium handling in man: relation to aldosterone excretion and plasma renin activity. Clin Sci Mol Med. 1975 Aug;49(2):139-47. doi: 10.1042/cs0490139. PMID: 1149405.

99) Franz S, Skopp G, Musshoff F. The effect of creatine ingestion on urinary creatinine concentration: Does supplementation mask a heavy dilution? Drug Test Anal. 2022 Jan;14(1):162-168. doi: 10.1002/dta.3165. Epub 2021 Oct 18. PMID: 34559477.

100) Ozdemir S, Sears CG, Harrington JM, Poulsen AH, Buckley J, Howe CJ, James KA, Tjonneland A, Wellenius GA, Raaschou-Nielsen O, Meliker J. Relationship between Urine Creatinine and Urine Osmolality in Spot Samples among Men and Women in the Danish Diet Cancer and Health Cohort. Toxics. 2021 Nov 1;9(11):282. doi: 10.3390/toxics9110282. PMID: 34822673; PMCID: PMC8625939.

101) Bankir L, Perucca J, Weinberger MH. Ethnic differences in urine concentration: possible relationship to blood pressure. Clin J Am Soc Nephrol. 2007 Mar;2(2):304-12. doi: 10.2215/CJN.03401006. Epub 2007 Jan 10. PMID: 17699429.

102) Worcester EM, Bergsland KJ, Gillen DL, Coe FL. Mechanism for higher urine pH in normal women compared with men. Am J Physiol Renal Physiol. 2018 Apr 1;314(4):F623-F629. doi: 10.1152/ajprenal.00494.2017. Epub 2017 Dec 20. PMID: 29357436; PMCID: PMC5966764.

103) Menezes CJ, Worcester EM, Coe FL, Asplin J, Bergsland KJ, Ko B. Mechanisms for falling urine pH with age in stone formers. Am J Physiol Renal Physiol. 2019 Jul 1;317(7):F65-F72. doi: 10.1152/ajprenal.00066.2019. Epub 2019 Apr 24. PMID: 31017011; PMCID: PMC6692718.

104) Suzuki S, Yoshida J, Takahashi T. Effect of testosterone on carbonic anhydrase and MG(2+)-dependent HCO3-stimulated ATPase activities in rat kidney: comparison with estradiol effect. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1996 Jun; 114(2):105-12. doi: 10.1016/0742-8413(96)00021-7. PMID: 8760605.

105) Toering TJ, van der Graaf AM, Visser FW, Buikema H, Navis G, Faas MM, Lely AT. Gender differences in response to acute and chronic angiotensin II infusion: a translational approach. Physiol Rep. 2015 Jul;3(7):e12434. doi: 10.14814/phy2.12434. PMID: 26149279; PMCID: PMC4552520.

106) Eloy L, Grünfeld JP, Bayle F, Bankir L, Ramos-Frendo B, Trinh-Trang-Tan MM. Papillary plasma flow in rats. II. Hormonal control. Pflugers Arch. 1983 Aug;398(3):253-8. doi: 10.1007/BF00657161. PMID: 6356035.

107) Lote CJ. Renal prostaglandins and sodium excretion. Q J Exp Physiol. 1982 Jul;67(3):377-85. doi: 10.1113/expphysiol.1982.sp002652. PMID: 7051084.

108) Parekh N, Zou AP, Jüngling I, Endlich K, Sadowski J, Steinhausen M. Sex differences in control of renal outer medullary circulation in rats: role of prostaglandins. Am J Physiol. 1993 Apr;264(4 Pt 2): F629-36. doi: 10.1152/ajprenal.1993.264.4.F629. PMID: 8476076.

109) Ho LL, Kench JG, Handelsman DJ, Scheffer GL, Stricker PD, Grygiel JG, Sutherland RL, Henshall SM, Allen JD, Horvath LG. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate. 2008 Sep 15;68(13):1421-9. doi: 10.1002/pros.20809. PMID: 18615486.

110) Huang YT, Zhou J, Shi S, Xu HY, Qu F, Zhang D, Chen YD, Yang J, Huang HF, Sheng JZ. Identification of Estrogen Response Element in Aquaporin-3 Gene that Mediates Estrogen-induced Cell Migration and Invasion in Estrogen Receptor-positive Breast Cancer. Sci Rep. 2015 Jul 29;5:12484. doi: 10.1038/srep12484. PMID: 26219409; PMCID: PMC4518221.

111) Dibas AI, Mia AJ, Yorio T. Aquaporins (water channels): role in vasopressin-activated water transport. Proc Soc Exp Biol Med. 1998 Dec;219(3):183-99. doi: 10.3181/00379727-219-44332. PMID: 9824541.

112) Toering TJ, Gant CM, Visser FW, van der Graaf AM, Laverman GD, Danser AHJ, Faas MM, Navis G, Lely AT. Sex differences in renin-angiotensin-aldosterone system affect extracellular volume in healthy subjects. Am J Physiol Renal Physiol. 2018 May 1;314(5): F873-F878. doi: 10.1152/ajprenal.00109.2017. Epub 2017 Jun 7. PMID: 28592435.

113) Hilliard LM, Nematbakhsh M, Kett MM, Teichman E, Sampson AK, Widdop RE, Evans RG, Denton KM. Gender differences in pressure-natriuresis and renal autoregulation: role of the Angiotensin type 2 receptor. Hypertension. 2011 Feb;57(2):275-82. doi: 10.1161/HYPERTENSIONAHA.110.166827. Epub 2010 Dec 28. PMID: 21189402.

114) Oelkers WKH, Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure, Steroids,Volume 61, Issue 4,1996, Pages 166-171, ISSN 0039-128X, https://doi.org/10.1016/0039-128X(96)00007-4.

115) Mishra JS, More AS, Gopalakrishnan K, Kumar S. Testosterone plays a permissive role in angiotensin II-induced hypertension and cardiac hypertrophy in male rats. Biol Reprod. 2019 Jan 1;100(1):139-148. doi: 10.1093/biolre/ioy179. PMID: 30102356; PMCID: PMC6335213.

116) Stachenfeld NS, Taylor HS. Effects of estrogen and progesterone administration on extracellular fluid. J Appl Physiol (1985). 2004 Mar;96(3):1011-8. doi: 10.1152/japplphysiol.01032.2003. Epub 2003 Dec 5. PMID: 14660504.

117) Stachenfeld NS. Sex hormone effects on body fluid regulation. Exerc Sport Sci Rev. 2008 Jul;36(3):152-9. doi:10.1097/JES.0b013e31817be928. PMID: 18580296; PMCID: PMC2849969.

118) Johannsson G, Gibney J, Wolthers T, Leung KC, Ho KK. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. J Clin Endocrinol Metab. 2005 Jul;90(7):3989-94. doi: 10.1210/jc.2005-0553. Epub 2005 Apr 12. PMID: 15827107.

119) Zhang D, Maalouf NM, Adams-Huet B, Moe OW, Sakhaee K. Effects of sex and postmenopausal estrogen use on serum phosphorus levels: a cross-sectional study of the National Health and Nutrition Examination Survey (NHANES) 2003-2006. Am J Kidney Dis. 2014 Feb;63(2):198-205. doi: 10.1053/j.ajkd.2013.07.012. Epub 2013 Sep 17. PMID: 24051078.

120) Hamm LL, Simon EE. Roles and mechanisms of urinary buffer excretion. Am J Physiol. 1987 Oct;253(4 Pt 2): F595-605. doi: 10.1152/ajprenal.1987.253.4.F595. PMID: 3310662.

121) Elalouf JM, Roinel N, de Rouffignac C. Effects of antidiuretic hormone on electrolyte reabsorption and secretion in distal tubules of rat kidney. Pflugers Arch. 1984 Jun; 401(2): 167-73. doi: 10.1007/BF00583877. PMID: 6473069.

122) Faroqui S, Levi M, Soleimani M, Amlal H. Estrogen downregulates the proximal tubule type IIa sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia. Kidney Int. 2008 May;73(10):1141-50. doi: 10.1038/ki.2008.33. Epub 2008 Feb 27. PMID: 18305465; PMCID: PMC2738940.

123) Everitt AV. The Urinary Excretion of Chloride, Phosphate, and Pigment in Ageing Male Rats. Gerontologia 1958;2:123–135.doi:10.1159/000210732.

124) de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol. 2011 Sep;22(9):1603-9. doi: 10.1681/ASN.2010121251. Epub 2011 Aug 18. PMID: 21852584; PMCID: PMC3171931.

125) Macova M, Armando I, Zhou J, Baiardi G, Tyurmin D, Larrayoz-Roldan IM, Saavedra JM. Estrogen reduces aldosterone, upregulates adrenal angiotensin II AT2 receptors and normalizes adrenomedullary Fra-2 in ovariectomized rats. Neuroendocrinology. 2008;88(4):276-86. doi: 10.1159/000150977. Epub 2008 Aug 4. PMID: 18679017; PMCID: PMC2677380.

126) Usberti M, Federico S, Di Minno G, et al. Effects of angiotensin II on plasma ADH, prostaglandin synthesis, and water excretion in normal humans. Am J Physiol. 1985 Feb;248(2 Pt 2):F254-9. doi: 10.1152/ajprenal.1985.248.2.F254. PMID: 3881995.

127) Maranduca MA, Clim A, Pinzariu AC, Statescu C, Sascau RA, Tanase DM, Serban DN, Branisteanu DC, Branisteanu DE, Huzum B, Serban IL. Role of arterial hypertension and angiotensin II in chronic kidney disease (Review). Exp Ther Med. 2023 Feb 16;25(4):153. doi: 10.3892/etm.2023.11852. PMID: 36911375; PMCID: PMC9996360.

128) Qadri F, Culman J, Veltmar A, Maas K, Rascher W, Unger T. Angiotensin II-induced vasopressin release is mediated through alpha-1 adrenoceptors and angiotensin II AT1 receptors in the supraoptic nucleus. J Pharmacol Exp Ther. 1993 Nov;267(2):567-74. PMID: 8246129.

129) Navar LG. Intrarenal renin-angiotensin system in regulation of glomerular function. Curr Opin Nephrol Hypertens. 2014 Jan;23(1):38-45. doi: 10.1097/01.mnh.0000436544.86508.f1. PMID: 24275770; PMCID: PMC3982859.

130) Nishimura K, Yoshino K, Sanada K, Beppu H, Akiyama Y, Nishimura H, Tanaka K, Sonoda S, Ueno H, Yoshimura M, Maruyama T, Ozawa H, Ueta Y. Effect of oestrogen-dependent vasopressin on HPA axis in the median eminence of female rats. Sci Rep. 2019 Mar 26; 9(1):5153. doi: 10.1038/s41598-019-41714-z. PMID: 30914732; PMCID: PMC6435644.

131) Stachenfeld NS, Splenser AE, Calzone WL, Taylor MP, Keefe DL. Sex differences in osmotic regulation of AVP and renal sodium handling. J Appl Physiol (1985). 2001 Oct; 91(4):1893-901. doi: 10.1152/jappl.2001.91.4.1893. PMID: 11568177.

132) Grikiniene J, Volbekas V, Stakisaitis D. Gender differences of sodium metabolism and hyponatremia as an adverse drug effect. Medicina (Kaunas). 2004;40(10):935-42. PMID: 15516815.

133) De Vries GJ, Wang Z, Bullock NA, Numan S. Sex differences in the effects of testosterone and its metabolites on vasopressin messenger RNA levels in the bed nucleus of the stria terminalis of rats. J Neurosci. 1994 Mar;14(3 Pt 2):1789-94. doi: 10.1523/JNEUROSCI.14-03-01789.1994. PMID: 8126571; PMCID: PMC6577591.

134) Stachenfeld NS, DiPietro L, Palter SF, Nadel ER. Estrogen influences osmotic secretion of AVP and body water balance in postmenopausal women. Am J Physiol. 1998 Jan; 274(1): R187-95. doi: 10.1152/ajpregu.1998.274.1.R187. PMID: 9458917.

135) Torres-Pinzon DL, Ralph DL, Veiras LC, McDonough AA. Sex-specific adaptations to high-salt diet preserve electrolyte homeostasis with distinct sodium transporter profiles. Am J Physiol Cell Physiol. 2021 Nov 1;321(5):C897-C909. doi: 10.1152/ajpcell.00282.2021. Epub 2021 Oct 6. PMID: 34613843; PMCID: PMC8616593.

136) Herzberg NH, Goudsmit E, Kruisbrink J, Boer GJ. Testosterone treatment restores reduced vasopressin-binding sites in the kidney of the ageing rat. J Endocrinol. 1989 Oct; 123(1):59-63. doi: 10.1677/joe.0.1230059. PMID: 2809490.

137) Pávó I, Varga C, Szücs M, László F, Szécsi M, Gardi J, László FA. Effects of testosterone on the rat renal medullary vasopressin receptor concentration and the antidiuretic response. Life Sci. 1995;56(14):1215-22. doi: 10.1016/0024-3205(95)00061-a. PMID: 7475899.

138) Wang K, Kestenbaum B. Proximal Tubular Secretory Clearance: A Neglected Partner of Kidney Function. Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1291-1296. doi: 10.2215/CJN.12001017. Epub 2018 Feb 28. PMID: 29490976; PMCID: PMC6086711.

139) Cowen LE, Hodak SP, Verbalis JG. Age-associated abnormalities of water homeostasis. Endocrinol Metab Clin North Am. 2013 Jun;42(2):349-70. doi: 10.1016/j.ecl.2013.02.005. Epub 2013 Apr 17. PMID: 23702406; PMCID: PMC3682932.

140) Mavani GP, DeVita MV, Michelis MF. A review of the nonpressor and nonantidiuretic actions of the hormone vasopressin. Front Med (Lausanne). 2015 Mar 24;2:19. doi: 10.3389/fmed.2015.00019. PMID: 25853137; PMCID: PMC4371647.

141) Tang C, Pathare G, Michael D, Fajol A, Eichenmüller M, Lang F. Downregulation of klotho expression by dehydration. Am J Physiol Renal Physiol. 2011; 301(4):F745–50. doi: 10.1152/ajprenal.00037.2011.

142) Kuro-O M. Phosphate and Klotho. Kidney Int Suppl. 2011 Apr;79(121):S20-3. doi: 10.1038/ki.2011.26. Epub 2011 Feb 23. PMID: 21346722; PMCID: PMC3260960.

143) Bachmann KN, Huang S, Lee H, Dichtel LE, Gupta DK, Burnett JC Jr, Miller KK, Wang TJ, Finkelstein JS. Effect of Testosterone on Natriuretic Peptide Levels. J Am Coll Cardiol. 2019 Mar 26;73(11):1288-1296. doi: 10.1016/j.jacc.2018.12.062. PMID: 30898204; PMCID: PMC6588352.

144) Chang AY, Abdullah SM, Jain T, Stanek HG, Das SR, McGuire DK, Auchus RJ, de Lemos JA. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol. 2007 Jan 2;49(1):109-16. doi: 10.1016/j.jacc.2006.10.040. Epub 2006 Nov 13. PMID: 17207730.

145) Glisic M, Rojas LZ, Asllanaj E, Vargas KG, Kavousi M, Ikram MA, Fauser BCJM, Laven JSE, Muka T, Franco OH. Sex steroids, sex hormone-binding globulin and N-terminal pro-brain natriureticin postmenopausal women. Int J Cardiol. 2018 Jun 15;261:189-195. doi: 10.1016/j.ijcard.2018.03.008. Epub 2018 Mar 6. PMID: 29551255.

146) Pan PP, Zhan QT, Le F, Zheng YM, Jin F. Angiotensin-converting enzymes play a dominant role in fertility. Int J Mol Sci. 2013 Oct 21;14(10):21071-86. doi: 10.3390/ijms141021071. PMID: 24152441; PMCID: PMC3821659.

147) Carrivick SJ, Walsh JP, Brown SJ, Wardrop R, Hadlow NC. Brief report: Does PTH increase with age, independent of 25-hydroxyvitamin D, phosphate, renal function, and ionized calcium? J Clin Endocrinol Metab. 2015 May;100(5):2131-4. doi: 10.1210/jc.2014-4370. Epub 2015 Mar 9. PMID: 25751107.

148) Need AG, O'Loughlin PD, Morris HA, Horowitz M, Nordin BEC. The Effects of Age and Other Variables on Serum Parathyroid Hormone in Postmenopausal Women Attending an Osteoporosis Center. The Journal of Clinical Endocrinology & Metabolism. 2004 April 1;89(4): 1646–49. doi.org/10.1210/jc.2003-031539.

149) Sharma S, Katz R, Dubin RF, Drew DA, Gutierrez OM, Shlipak MG, Sarnak MJ, Ix JH. FGF23 and Cause-Specific Mortality in Community-Living Individuals-The Health, Aging, and Body Composition Study. J Am Geriatr Soc. 2021 Mar;69(3):711-717. doi: 10.1111/jgs.16910. Epub 2020 Nov 10. PMID: 33170519; PMCID: PMC8175094.

150) Laffer CL, Elijovich F, Sahinoz M, Pitzer A, Kirabo A. New Insights into the Renin-Angiotensin System in Chronic Kidney Disease. Circ Res. 2020 Aug 14;127(5):607-609. doi: 10.1161/CIRCRESAHA.120.317624. Epub 2020 Aug 13. PMID: 32790525; PMCID: PMC7430039.

151) Tank JE, Vora JP, Houghton DC, Anderson S. Altered renal vascular responses in the aging rat kidney. Am J Physiol. 1994 Jun;266(6 Pt2):F942-8. doi: 10.1152/ajprenal.1994.266.6.F942. PMID: 8023973.

152) Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol. 2008 Sep;19(9):1721-31. doi: 10.1681/ASN.2008010021. Epub 2008 Jul 2. PMID: 18596120; PMCID: PMC2518442.

153) Arruda JA, Stipanuk S, Walter R, Kurtzman NA. Effect of vasopressin administration on sodium excretion and plasma phosphate concentration. Proc Soc Exp Biol Med. 1977 Jul;155(3):308-13. doi: 10.3181/00379727-155-39796. PMID: 877126.

154) Tozuka K, Hara Y, Moriguchi H, Kikuchi T, Tokue A. [The role of urine pH in the occurrence of phosphaturia]. Hinyokika Kiyo. 1989 Sep;35(9):1475-8. Japanese. PMID: 2816612.

155) Sachse A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol. 2007 Sep;18(9):2439-46. doi: 10.1681/ASN.2007020149. Epub 2007 Aug 8. PMID: 17687073.

156) Lu X, Hu MC. Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease. Kidney Dis (Basel). 2017 Jul;3(1):15-23. doi: 10.1159/000452880. Epub 2016 Nov 17. PMID: 28785560; PMCID: PMC5527179.

14. Supplementary Material / Appendices

1. RENAL TRANSPORTERS	Female	Estrogen/Progesterone Effects	Male	Androgen Effects	References
Pool size of transporters in proximal tubules (PT)	↓ (NaPi2, NHE3, cldn2, a.o.)	direct / indirect	↑ (NaPi2, NHE3, cldn2, a.o.)	direct / indirect	6
Pool size of transporters in distal tubules (DT)	↑ (NCC, NKCC2, SPAK, AQP2, cldn7)	direct / indirect	↓ (NCC, NKCC2, SPAK, AQP2, cldn7)	direct / indirect	6
Upregulation of OATs and OCTs (Organic Anion- and Cation Transporters) - mainly in S3-segment of PT	OAT2, OAT5, SGLT1, MRP3	OAT2, OAT5	OAT1, OAT3, OCT2, OATP1, OATP1a1, OATP3a1, MRP4, MATE1, PG1/MDR1, MDR1a, URAT1, BCRP, CLDN-1, -2, -11, -16	OAT1, OAT3, OCT2, OATP1a1, OATP3a1, URAT1, MRP4, MATE1	6, 109
Downregulation of OATs and OCTs - mainly in S3-segment of PT	OAT1, OAT3, OCT2, OATP1, URAT1, MATE1, MRP4, PGy1/MDR1, MDR1a, OATP1a1, OATP3a1, BCRP, CLDN-1, -2, -11, -16	OAT1, OAT3, OCT2, BCRP, MATE1	OAT2, OAT5, SGLT1	OAT2, OAT5, SGLT1	6
Aquaporins (AQP) - only AQP2 is responsive to AVP	AQP1↓, AQ2↓, AQP3↑	AQP1↓, AQ2↓, AQP3↑	AQP1↑, AQ2↑, AQ3↓	AQ3↓	6, 110, 111
Sex Hormone receptors (humans)	ERβ (IST, CD, PT) PgR B (Glo, DT, IST) AR (DT) ↓		ERα (IST, CD) ERβ (IST, CD, PT) PgR B (Glo, DT, IST) AR (DT) ↑		6

Appendix 1: Sex differences and influence of sex hormones on renal membrane transporters.

2. URINE PARAMETERS	Female	Estrogen/Progesterone Effects	Male	Androgen Effects	References
24h Urine volume	Inconsistent (↑)		in 4/9 studies: 10-14% ↓ in 5/9 studies: ± 5%, not significant		85
Urine concentration	↓	indirect	↑	indirect	85
Water turnover / -excretion	↑		↓		97
Natriuresis (Sodium excretion)	↑	P: direct (Prox. & Dist. Tubule) ↓ P: indirect (ALD-Antagonist) ↑ E: ↓	↓	5α-DHT → ATII mediated NHE3↑ T→ ENaC mRNA↑ T → ADH-effects ↑ → reabsorption Na^+, HCO_3, fluid↑	6, 98, 99
Urine osmolality	↓	indirect	↑ (+21-39%)	indirect	6, 85, 100
Urine osmolality - effect of aging	decline > 50 years		decline > 40 years		85
Urinary excreted total osmotic load	↓		↑		85
Urine Creatinine	↓	indirect: lean muscle↓ OCT2↓ MATE↓	↑	direct stimulation indirect: lean muscle ↑ ADH↑, OCT2↑,MATE1↑	6, 85, 100, 101
Urine pH **→ pH↓ with aging (0 - 50 years)**	↑ Crucial GI anion uptake ↑		↓		102
Tubular H^+, Cl^- - and HCO_3^- - Transport	AE1/Band 3, NHE1, NHE2, Pendrin↑	E: Cytosolic carbonic anhydrase↑	CLDN-1, -2, -11, -16↑	Cytosolic carbonic anhydrase ↓	6, 102, 103, 104

Appendix 2: Physiological sex differences and influence of sex hormones on basic urinary parameters.

3. KIDNEY PARAMETERS	Female	Estrogen/Progesterone Effects	Male	Androgen Effects	References
Renal mass	↓		↑	anabolic action on PT cells	6
Number of nephrons/kidneys	no sex-difference		no sex-difference		6
GFR - Glomerular Filtration Rate	↓		↑		6
GFR response to ATII	↓↓		↓		105
ERPF - Effective renal plasma flow ($ml/min/1.73m^2$)	↓ (-20%)		↑		6, 105
ERPF response to ATII	↓		↓↓		105
PPF - Papillary Plasma Flow	↑	E indirect: vasodilator PG↑	↓	T (+ATII) ↓	106
Renal antioxidative capacity / antioxidative enzyme expression	↑ eNOS, Metallothionein, MnSOD, Carbonic Anhydrase	E: ROS↓, Endothelin↓, NO↑,	↓ eNOS, Metallothionein, MnSOD, Carbonic Anhydrase	NO ↓ renal ROS ↑	6,7,8
Renal methylation capacity	↑	E: PEMT/Choline↑	↓		3,4
GFR Decline > 50 years (Renal injury proness)	↓	protective antioxidative methylation /choline↑	↑	AR-mediated Apoptosis of PT cells; Telomere shortening	6, 33
Tubular dysfunction / Excretion of low MW Proteins	↓		α- and β-Microglobulins, Angiotensinogen ↑		6
Renal Prostaglandines → Antagonism to AVP/ AQ2 action (Cellular Ca-uptake ↓/ Adenylatcyclase↓) → Natriuresis / Waterdiuresis ↑ → Ionic Permeability ↑ → Corticomedullary Solute Gradient ↓ Cortex: Renin/RPF/GFR ↑ Medulla: PG regulate papillary osmolality → PG production (Phospholipase A2) is activated by high extracellular osmolality, Kinins, AVP, ATII → PG production inhibited by corticosteroids	↑ (Vasodilator PGs, attenuating ATII-effects on medullary flow)		↓		85, 107, 108

Appendix 3: Physiological sex differences and influence of sex hormones on basic renal parameters.

4. SYSTEMIC PARAMETERS	Female	Estrogen/Progesterone Effects	Male	Androgen Effects	References
Blood Pressure	Physiolgical and transdermal E2: ↓	E Vasodilatation, NO↑, AT2R↑ P Na+-Excretion ↑ via ALD-Antagonism [a]	↑	permissive on ATII AT1R/AT2R Ratio↑	40, 112, 113, 114, 115
	High dose/oral E2, Gestagens: ↑	plasma ALD↑			
NO/Vasodilation	↑	E ↑ crosstalk with MasR P ↑↓ (situative)	↓	NO ↓	6, 7, 40
Extracellular Volume	↓ (F < M)	E/P direct ↑ E indirect (RAS↑, ADH↑)	↑	direct ↑: Na^+ - retention at proximal tubules indirect↑: - permissive effect on HGH-induced Na^+ - retention - BNP↓ → AVP-Inhibition ↓	112, 116, 117, 118
Plasma Volume	65 ml/kg	E ↑ (TER-Albumin ↓) P ↓	70 ml/kg	?	116, 117
Serum Phosphate (PO_4, sP)	Progressive decline until 45 years <45 years: no sex difference >45 years: ↑	E ↓, NaPT-IIa ↓, Ca-reabsorption↑	Progressive decline until 45 years <45 years: no sex difference >45 years: ↓	T ↓ (?)	17, 58, 71, 119, 120 121, 122, 123, 124,
Whole body metabolic rate	↓		↑		6
Nitrogenous waste products (Creatinine, Urea, Uric acid)	↓		↑		6

[a] *Despite potentially elevating Ang II and AT1R levels, progesterone does not appear to raise blood pressure in response to ATII in women.*[40]

Appendix 4: Physiological sex differences and influence of sex hormones on fluid distribution parameters.



Appendix 5: Influence of age on medians and ICRs of uCR and TWuAs.
All samples with age indication, $uAs_{UC} \leq 500$ µg/L, and uCR < 4.5 g/L (n=5585, females n= 2967, males n = 2618) were classified into seven identical age groups as in Fig. 1 (0-10 y, 11-20 y, 21-35 y, 36-50 y, 51-65 y, 66-80 y, >80 y). The supplementary Excel file gives detailed descriptive statistics for each age group. Medians (squares) ± ICRs (vertical error bars) were calculated for uCR (A), uAs_{UC} (B), uAs_C (C), and uAs_N (D) in sex-aggregate data. Horizontal age error bars were omitted as age SEs in individual age bands ranged from 0.09 to 0.53 years and thus were too small for visual delimitation from measurement points. Sex ratios of mean values are illustrated in the inlays of Figures A-D. The sample sizes of the individual subgroups are shown in parentheses next to the data points in (D).



	Sex	valid N	Mean ± Std.	Median	Modal	Minimum	Maximum
uAsUC (µg/l)	F	2907	17.8 ± 32.9	7.4	1.5	0.99	412
	M	2493	26.9 ± 46.6	11	3.5	0.96	484
uAsC (µg/g uCR)	F	2907	25.4 ± 44.6	11.6	10	1.07	741
	M	2493	23.9 ± 36.8	10.9	11	0.81	420
uAsN (µg/1g uCR)	F	2907	23.1 ± 42.6	10.2	3.8	1.2	724.3
	M	2493	23.6 ± 36.5	10.7	3.8	0.9	408.2

Appendix 6: Quantitative sex differences of TWuAs within uAs_{UC}, uAs_C, and uAs_N.
All n=5400 samples (2493 males, 2907 females) were in the age band 14-82 years, < 500 µg/L uAs_{UC}, and uCR < 4.5 g/L. Bars/Error bars: means/SE of log-transformed, sex-differentiated TWuAs data. The significance (p) of sex differences within each log-transformed TWuAs dataset was established by Mann-Whitney U test. In addition, linear statistical data are given in the table.



Appendix 7: Increase in As_N with age between the end of puberty and the seventh decade of life.
Medians and ICR of 5 age bands are shown. Linear regression revealed an average annual increase of 0.28 µg/1 g uCR uAs_N. However, the rule of continuous increment of uAs_N with age illustrated here does not seem to hold at both ends of life since infants had higher uAsN than adolescents, and there is a drop in uAsN among the very elderly compared to younger seniors (Fig. 1).

≥ 14 years uAs_{UC} <500 (µg/l)	n	Pearson correlation	uCR (g/L)	uAs_{UC} (µg/l)	uAs_C (µg/g CR)	uAs_N (µg/1g CR)
Age (All)	5449	R	-0.16	0.03	0.09	0.09
		p (2-tailed)	<.001	.022	<.001	<.001
Age (Female)	2928	R	-0.18	0.04	0.09	0.08
		p (2-tailed)	<.001	.053	<.001	<.001
Age (Male)	2521	R	-0.17	0.03	0.1	0.09
		p (2-tailed)	<.001	.2	<.001	<.001

≥ 14 years uAs_{UC} <500 (µg/l)	n	Pearson correlation	LN uCR (g/L)	LN uAs_{UC} (µg/l)	LN uAs_C (µg/g CR)	LN uAs_N (µg/1g CR)
Age (All)	5449	R	-0.11	0.04	0.13	0.11
		p (2-tailed)	<.001	.005	<.001	<.001
Age (Female)	2928	R	-0.13	0.01	0.11	0.09
		p (2-tailed)	<.001	.649	<.001	<.001
Age (Male)	2521	R	-0.11	0.07	0.15	0.13
		p (2-tailed)	<.001	.001	<.001	<.001

Appendix 8: Pearson correlation of age with uCR and TWuAs.
Pearson correlation coefficients (R) and significance (p) are given for linear data (upper table) and log data closer to the normal distribution (lower table).



Appendix 9: Sex- and age-differentiated efficacy of standardization in trimmed data sets.
S-PFRA was performed in the age/sex subsets of Fig. 3 following the exclusion of outliers. R^2 and b values are compared

between uAs_{UC},uAs_{C}, and uAs_{N}. Outliers were defined as all values above the upper fences (UF) in boxplots with UF = 3. Quartile + 1.5 × IQR.



"U_{osm} in men and women in the different age categories in subjects of study D during the run-in period. B: U_{osm} in men and women in study S according to the different classes of CKD (I to V). Means ± SE for men (•) and women (○). Dashed lines indicate isoosmolality to plasma. Relatively large SEs in the first age and CKD classes are probably due to the small number of subjects of each sex in these classes. When SEs are not visible, they are smaller than the symbols. Comparison by two-way ANOVA (sex and CKD, or sex and age). The sex difference was significant in both cases." [73]

Appendix 10: Effect of age on sex-differentiated urine osmolality (Perucca J et al., 2006).
Reproduction of original Figure 2 A of "Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease," Perucca J, et al. (2006).[73]